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Abstract 
The Immunity-Related GTPases (IRGs) are a family of dynamin-like proteins 
found in vertebrates that play critical roles in cell-autonomous resistance to bacteria and 
protozoa.  The IRGs are divided into two subfamilies, with the GMS IRGs exerting a 
regulatory function over the GKS IRGs, affecting GKS IRG expression, localization, and 
ultimately function.  The profound loss of host resistance seen in mice lacking the GMS 
protein Irgm1 suggests that GMS IRGs may additionally have broader functions beyond 
the regulation of GKS IRGs, though the nature of these functions remains poorly 
understood.  In this dissertation, we address the regulatory functions of GMS IRGs in 
mouse cells. 
We first addressed regulation of GKS IRGs (Irga6 and Irgb6) by GMS IRGs 
(Irgm1 and Irgm3).  We found that in both fibroblasts and macrophages lacking these 
GMS IRGs, that the GKS IRGs relocalized to form punctate structures that were 
ubiquitin-, p62-, and LC3-positive.  A biochemical analysis indicated that the GKS IRGs 
were directly ubiquitinated through K63 linkages.  Collectively, these results suggested 
that GMS IRGs regulate aggregation of GKS IRGs and their transfer to autophagosomes 
through one of at least two possible mechanisms -- by the direct association of GMS 
IRGs with GKS IRGs to block their aggregation that subsequently leads to autophagic 
removal, and/or by directly promoting autophagic removal of spontaneously forming 
GKS aggregates.  The latter hypothesis was addressed using a series of complementary 
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assays, which ultimately showed that absence of Irgm1 has no effect on the maturation 
of autophagosomes in fibroblasts, and only a very small and statistically insignificant 
effect in macrophages.  Thus, we conclude that the major mechanism through which 
GMS IRGs regulate GKS IRGs is by directly inhibiting their aggregation, rather than 
through general effects on autophagic initiation or maturation of GKS IRG-containing 
autophagosomes. 
We also addressed the possibility of broad regulatory functions of GMS IRGs 
beyond the regulation of GKS IRGs by examining whether GMS IRGs can affect another 
family of dynamin-like GTPases, the guanylate-binding proteins (GBPs).  Despite no 
previous evidence of interactions between these two protein families, we found that the 
absence of GMS IRGs had striking effects on the localization of the murine Gbp2, 
leading it to colocalize with GKS IRG aggregates formed as a consequence of GMS IRG 
deficiency.  We further demonstrated that unlike the GKS IRGs, Gbp2 was not tagged 
with K63-linked ubiquitin chains, which might have targeted it for specific 
macroautophagy, implying that Gbp2 is not aggregating in the absence of Irgm1.  We 
then showed both that Gbp2 forms puncta in the presence of generic protein aggregates, 
and that guanylate-binding proteins including Gbp2 promote the degradation of GKS 
IRG protein aggregates.  These findings suggest that GMS IRGs do not exert direct 
control over GBPs, but rather that GBPs are involved in the macroautophagic 
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degradation of protein aggregates as a primary function, and are thus influenced 
indirectly by GMS IRGs. 
In total, our experiments contribute to the understanding of regulatory 
interactions among GMS IRGs, GKS IRGs, and GBPs.  These results will be 
important in establishing the mechanisms through which these important 
families of proteins influence eradication of bacterial and protozoan pathogens 
through key innate immune mechanisms. 
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1. Introduction  
1.1 Interferon-mediated innate immunity 
1.1.1 The role of interferons in the innate immune response 
In 1957, a substance was discovered which conferred a protective effect against 
viral infection on cells [1].  This protein was dubbed “interferon” for its ability to 
interfere with viral replication.  The subsequent discovery of related cytokines, and the 
addition of in silico analyses of entire genomes, led to the realization that the original 
interferon was a member of a large family of pro-inflammatory cytokines that induce 
immune responses. 
Interferons (often abbreviated as IFNs) can be divided into two categories, type I 
interferons and type II interferons.  Type I interferons can be further divided into related 
subfamilies, including the more commonly studied IFN-α’s and IFN-β, along with the 
more recently characterized IFN-ε, IFN-κ, and IFN-ω (all found in Homo sapiens) and 
other families found in other species (compiled and described by ref [2]).  Type I 
interferons are vital to mounting a response to viral challenges; once pathogen-
associated molecular patterns, such as viral envelope proteins or double stranded RNA, 
are detected by Toll-like receptors, signaling pathways are induced that activate the 
transcription factor NF-kappaB, which induces expression of innate immune cytokines 
such as type I interferons [3].  In contrast, there is only one type II interferon, IFN-γ, and 
this cytokine is expressed largely by T lymphocytes, in response to presented antigens, 
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and natural killer cells, in response to other cytokines [4], including IFN-γ itself [5].  The 
type II interferon response is most relevant to the work presented in this dissertation, 
and will be the focus of this discussion. 
The cellular response to interferon induction is immediate and profound.  
Interferons function to promote the transcription of hundreds of genes with anti-
pathogen activity, including antimicrobials and antivirals, chemokine/cytokine 
signalers, and antigen presentation pathways, while simultaneously repressing 
transcription of anabolic pathways such as lipid metabolism and the cell cycle [6-8].  As 
much as 25% of the overall macrophage transcriptome is affected by the interferon 
response [6].  In some cases, even cells which are not normally involved in immunity, 
such as astrocytes, can be induced by interferons to exhibit immune functions [9].  The 
signaling pathways which mediate these powerful changes in overall transcription 
within interferon-stimulated cells will be outlined in the next section. 
1.1.2 Interferon signaling pathways 
1.1.2.1  The canonical type I interferon signaling pathway 
All of the many kinds of type I interferons bind the same cell surface receptor, 
called the type I cell surface receptor [2].  This receptor is composed of two subunits, 
IFNAR1 and IFNAR2; each of these subunits is associated with separate members of the 
Janus-activated kinase (JAK) family -- IFNAR1 with TYK2 and IFNAR2 with JAK1 [10].  
Upon binding a type I interferon ligand, IFNAR1 and IFNAR2 dimerize and 
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autophosphorylate [10], which leads to activation of the two associated JAK proteins 
[11].  The JAK kinases then activate several other downstream signaling cascades. 
The canonical and most-studied of these downstream pathways is mediated by 
STAT (signal transducer and activator of transcription) proteins.   STATs 1-6 are all 
facilitators of the type I interferon response [12], although some are restricted to certain 
cell types [13-16].  JAK kinases phosphorylate STAT proteins in response to interferon 
stimulation, whereupon phosphorylated STAT proteins form homo- or hetero- dimers, 
which may also complex with other cofactors [10].  These complexes serve as 
transcription factors that recognize and bind to specific elements upstream of the 
promoters of interferon effector proteins [17].  The canonical STAT complex, called the 
ISGF3 complex (interferon-stimulated gene factor 3), contains a heterodimer of STAT1-
STAT2 bound with the cofactor IRF9 [18,19]; this complex binds the sequence called the 
interferon-stimulated response element (ISRE) found upstream of many interferon-
induced genes [17]. 
1.1.2.2  The canonical type II interferon signaling pathway 
The canonical type II interferon signaling pathway is very similar to that of type I 
interferons, involving a separate cell surface receptor which also activates the signaling 
cascade of JAK kinases followed by STAT protein complexes.  The cell surface receptor 
involved in the type II interferon response also consists of two subunits, IFNGR1 and 
IFNGR2; these associate with the kinases JAK1 and JAK2, respectively [11,20-22].  
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Similarly to the type I cell surface receptor, IFNGR1 and IFNGR2 dimerize and 
autophosphorylate in the presence of the interferon-γ ligand, which activates the two 
JAK proteins [10,21].  In contrast to the type I signaling pathway, however, activation of 
JAK1 and JAK2 leads to phosphorylation of only STAT1, on Tyr701, which then forms a 
homodimer [4,12,17].  This STAT1 homodimer acts as a transcription factor which binds 
a specific sequence call the gamma-activated sequence, or GAS [4,17,23].  Thus, in 
contrast to type I interferons which induce transcription of genes with many kinds of 
upstream elements, type II interferon STAT-mediated signaling specifically and only 
induces transcription of genes with upstream GAS elements. 
1.1.2.3  STAT serine 727 phosphorylation pathways 
While the canonical JAK-STAT signaling pathway is sufficient for inducing 
transcription of interferon-stimulated genes, a stronger transcriptional response can be 
engendered by the phosphorylation of STAT proteins on their serine 727 residue [24,25].  
Mice engineered with a STAT1-S727A mutation succumb more readily to Listeria 
monocytogenes infection, indicating that this phosphorylation event plays an important 
role in innate immunity to bacterial infection [26].  The mechanisms of Ser727 
phosphorylation are currently poorly understood, but in the case of interferon-γ 
signaling are known to involve the activation of a cascade beginning with JAK1/2 which 
eventually causes activation of PI3K, which ultimately activates PKC-δ, which is 
necessary for phosphorylation of STAT1 Ser727 [27-29].  The activation of PI3K by the 
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interferon signaling pathway is intriguing, as PI3K plays an important role in a variety 
of signal transduction pathways, including being an upstream activator of mTOR 
[30,31], a signal integrating protein which upregulates anabolic pathways while 
inhibiting catabolism [32,33].  mTOR and PI3K will be discussed further in section 1.4 of 
this dissertation, concerning the process of macroautophagy. 
1.1.2.4  Non-canonical interferon signaling pathways 
It is worth mentioning that in addition to the STAT-mediated signaling pathways 
just described, interferons also promote alternative signaling pathways which are 
independent of STAT activation, and in some cases independent of JAK kinases.  These 
pathways are just beginning to be fully described, and may involve CRK proteins, p38 
mitogen-activated protein kinases (p38 MAPKs), or PI3 kinases (for a review, see ref 
[34]).  One non-canonical pathway relevant to the work discussed in this dissertation is a 
JAK-independent interferon-γ signaling cascade which has been shown to play a role in 
bacterial defense [35-37].  This cascade involves the MEK-ERK signaling pathway, which 
activates the transcription factor  CCAAT/enhancer-binding protein-β (C/EBP-β) [35].  
This protein binds to an enhancer sequence (separate from the canonical GAS sites) 
called the gamma-IFN-activated transcriptional element, or GATE [36].  Interestingly, 
STAT1 is necessary for this process, although the mechanism is unknown [35].  The 
C/EBP-β – GATE pathway may be important to the induction of macroautophagy [37], 
and will be discussed further in section 1.4 of this dissertation. 
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In summary, type I and type II interferons are important pro-inflammatory 
cytokines which upregulate the transcription of hundreds of effector proteins in 
response to viral and bacterial challenges, while repressing cell growth pathways.  
Interferon signaling pathways usually involve JAK kinases that promote the formation 
of STAT-containing transcription factors which bind specific enhancer sequences found 
upstream of promoters.  Future work in the field of interferon signaling will continue to 
uncover novel signaling pathways, as well as elucidate the complex crosstalk between 
pathways activated by interferon cell surface receptors. 
1.2  Immunity-related GTPases 
1.2.1  Genetic  and proteomic features of the IRG family 
Among the many effector proteins induced by interferons is a family of ~47kDa 
GTPases known as the Immunity-Related GTPases, or IRGs.  Members of this family 
have been found in mammals and some fish, though the number of genes per species 
varies widely, from 2 (in Homo sapiens) to 23 (in the C57Bl/6 strain of Mus musculus) 
[38,39].  Most of the known members are transcriptionally induced by interferon 
signaling pathways via multiple interferon-stimulated response elements (ISREs) and γ-
activated sequence (GAS) elements in their promoter regions [38,40].  Notable 
exceptions which are not induced by interferon include members of the C subfamily [38] 
(see section 1.2.3, IRG subfamilies) and the human gene IRGM [39,41], all of which are 
constitutively expressed; additionally, members of the murine M subfamily are 
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constitutively expressed at very low levels but undergo strong expression when induced 
by interferon-γ (Taylor lab, unpublished data).  Intriguingly, some IRG genes of the B 
subfamily in Mus musculus are expressed together on tandem transcripts (Irgb1-Irgb2 
and Irgb4-Irgb5), although it is unknown if these transcripts are translated into one or 
two polypeptide chains [38]. 
The crystal structure of Irga6 is the only currently solved IRG protein structure, 
but it is thought to be a good model for other IRGs.  This structure contains mainly 
alpha-helices, and consists of three domains: a short three-helix N-terminal domain, a 
GTP-binding domain, and an eight-helix C-terminal domain [42].  It should be noted 
that the most conserved domain across species is the G domain [38]; certain family 
members, most notably human IRGM, encode very truncated N-terminal and C-
terminal domains [38]. 
1.2.2  IRGs belong to the dynamin superfamily 
The dynamins are a superfamily of GTPases which share similar biochemical 
functions.  These include involvement in vesicle formation, vesicle trafficking, and other 
aspects of lipid membrane remodeling, due to the ability of dynamins to bind and alter 
lipid membranes in various intracellular membrane-bound compartments, often after 
forming self-dimers and/or oligomers [43-45].  These abilities may be related to the 
unique functionality of the GTP-binding domain of dynamins.  G domains are 
commonly thought of as biochemical “switches,” with GTP-bound proteins being in the 
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biologically “active” state, while GDP-bound proteins are in an “inactive” state [46]; the 
canonical example is the Ras family of signal transducers.  The dynamins, however, 
while still demonstrating some switch-like activity [47], are thought to primarily employ 
their GTP-binding ability differently.  Instead of utilizing GTP only as a biochemical 
on/off switch, dynamins are thought to exploit the energy of GTP hydrolysis to undergo 
conformational changes which are necessary to their biological function, thus classifying 
them as “mechanoenzymes” [48].  Thus, the GTP-bound state of a dynamin can be 
thought of both as an “on” state, and as a “ready” state which can be quickly activated 
to perform necessary functions.   
These characteristic features of dynamins are in fact mirrored in immunity-
related GTPases, thus placing them functionally in the dynamin superfamily (though it 
should be noted there is little sequence homology outside of the G domain).  The G 
domain of the immunity-related GTPases has been shown to possess GTPase 
functionality [49,50], although often only after dimerization, implying that IRGs share 
the dynamin penchant for self-oligomerization [42,49].  Additionally, localization of IRG 
proteins within the cell is, like dynamins, largely confined to intracellular membranes, a 
trait which is mediated both by lipidation sites found in certain family members 
[38][Taylor lab, unpublished data], and by amphipathic alpha-helices  in the C-terminal 
domain (e.g. the αK helix of Irgm1) [51].  The lipidation sites which have so far been 
discovered include N-terminal MGxxxS myristolation sequences in eleven murine IRG 
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proteins [38,52]; of these, Irga6 is confirmed myristolated in vitro [53].   Additionally, 
murine Irgm1 has been identified as possibly being S-acylated [54], and has been 
confirmed both to be palmitoylated near the C-terminal domain αK helix, and that this 
motif is necessary for proper membrane localization (Taylor lab, unpublished data).   
While IRGs share mechanisms of localization, the specific membranes to which 
they migrate differ by family member in Mus musculus.  For instance, Irgm1 and Irgm2 
localize to the Golgi apparatus [51,55,56], and Irgm1 is also seen very weakly on 
mitochondrial and lysosomal membranes [51,57,58].  In contrast, Irgm3 localizes 
strongly to the endoplasmic reticulum (ER), to discrete vesicles in the  near vicinity of 
the ER, and to lipid droplets [50,59].  Irga6 and Irgb6, like Irgm3, appear predominately 
ER localized [51,60].  Presumably, these difference cellular locations instruct discrete 
cellular functions. 
Interestingly, a functional GTPase domain is not necessary for correct initial 
localization of any of these IRGs [50,51], and thus activation of these proteins is 
unnecessary for proper initial localization.  This finding implies that these membranes 
may be “holding pens” for inactive IRGs, and raises the interesting question of whether 
activated, GTP-hydrolyzing IRGs might relocate to other membranes.  This has been 
found to be the case, as in cells containing membrane-bound pathogens, many IRGs 
relocate to pathogen-containing compartments, where they are thought to modulate 
membrane processing [55,61,62].  This processing, in turn, is postulated to impact the 
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survival of membrane-bound pathogens.  We will further discuss these influences of 
IRGs on innate immunity in section 1.2.4; however, before we can fully discuss this 
topic, it is necessary to describe the various subfamilies of IRGs. 
1.2.3  IRG subfamilies 
Members of the IRG family are divided into nine subfamilies (named with the 
letters A-G, M, and Q) based on sequence similarities (Table 1) [38].  Note that IRG 
names are derived from the stem Irg + subfamily name + number (for example, Irgm3 is 
the third member of the M subfamily of IRGs).  As mentioned above, IRGs are members 
of the dynamin superfamily, whose G domain is thought to be very important to their 
overall function; thus, major sequence differences in the G domain are the primary basis 
for the IRG subfamily classification [38]. 
There are two subfamilies of IRGs which contain striking sequence variations in 
their G domain.  One of these, the Q (or quasi-) subfamily, has no members with GTP-
binding motifs in their G domains, and thus its members are not well-studied [38]; this 
subfamily is not relevant to this dissertation and will not be further discussed.  The other 
subfamily with a significant sequence variation in the G-domain is the M subfamily.  In 
this group, a canonical peptide sequence in the p-loop of switch I of the conventional 
dynamin GTP-binding domain, glycine-lysine-serine, a sequence which is responsible 
for stabilizing the bound nucleotide, has been changed to a glycine-methionine-serine 
sequence [40].  Members of the M subfamily of IRGs are often referred to as GMS IRGs, 
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while IRGs containing the conventional p-loop sequence are called GKS IRGs; this 
terminology will often be used in this dissertation. 
This unique p-loop modification of GMS IRGs is thought to impact their GTP-
binding capabilities as compared to GKS IRG subfamilies, a hypothesis which is 
supported by studies of the murine proteins Irgm3 and Irga6.  Irgm3 is a member of the 
GMS IRG subfamily and contains the non-canonical p-loop sequence; it has been found 
to be greater than 90% GTP-bound in vivo [50].  In contrast, Irga6, which contains the 
conventional GKS p-loop sequence, displays a marked preference for binding GDP [49].  
Utilizing the dynamin GTP-binding model, wherein GTP-bound dynamins can be 
readily activated, these findings imply that GMS IRGs are nearly always active within 
the cell, whereas GKS IRGs are largely inactive, but activatable by changing cellular 
conditions.  The implications of this finding on the roles of these two types of IRGs in 
innate immunity will be discussed further in section 1.2.4. 
The GKS IRGs comprise the remaining seven subfamilies of IRGs.  Four of these 
subfamilies are not relevant to this dissertation, and will only be briefly described here 
for completeness.  These subfamilies include subfamilies E – G, which have only been 
found in fish [38] and are thus not relevant to the mammalian systems utilized in this 
work; and the C subfamily, which exhibits no obvious functional relationship to other 
IRGs, is not induced by interferon, has only been found to be expressed in male testes, 
and is isolated on a separate chromosome from the other two IRG loci [38].  Since this  
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Table 1:  IRG Subfamilies.  Information summarized from ref. [38]. 
P-loop 
sequence 
Subfamily 
Name 
Species Notable Features 
Relevant 
to this 
work? 
GMS M 
Mus musculus 
Canis familiaris 
Pan troglodytes 
Homo sapiens 
Non-canonical sequence 
in GTP-binding domain 
Yes 
GKS 
A Mus musculus  Yes 
B 
Mus musculus 
Canis familiaris 
 Yes 
C 
Mus musculus 
Canis familiaris 
Pan troglodytes 
Homo sapiens 
Constitutively expressed 
in male testes 
No 
D 
Mus musculus 
Canis familiaris 
 Yes 
E Danio rerio  No 
F 
Tetraodon nigriviridis 
Fugu rubripes 
Danio rerio 
 No 
G Danio rerio  No 
GVS, 
GSS, 
GLV, or 
none 
Q 
Danio rerio 
Mus musculus 
Homo sapiens 
G domain lacks GTP-
binding motifs 
No 
 
subfamily is not thought to play a role in innate immunity, it will not be discussed 
further. 
 13 
The three subfamilies of GKS IRGs which are relevant to this work include 
subfamilies A, B, and D, which have been found in both Mus musculus and Canis 
familiaris, but notably not in Pan troglodytes or Homo sapiens [38].  More on the functions 
of these subfamilies, along with the GMS IRGs, in innate immunity will be discussed in 
section 1.2.4. 
1.2.4  The IRG family in innate immunity 
1.2.4.1  Innate resistance to membrane-bound pathogens 
As we have discussed above, the immunity-related GTPases are a family of 
small, interferon-inducible, functional GTPases belonging to the dynamin superfamily of 
membrane-processing proteins.  The induction of IRGs by cytokines which induce 
innate immune responses, along with their localization to membranes, suggest that IRGs 
might be involved in immune defense against intracellular membrane-bound pathogens.  
This has been found to be true, as absence of murine Irgm1, a member of the GMS IRGs, 
leads to a striking susceptibility to multiple membrane-bound intracellular organisms, 
including Toxoplasma gondii [55,63], Salmonella typhimurium [64], Listeria monocytogenes 
[63], Chlamydia trachomatis [65,66], and Mycobacterium species [67,68].  Loss of Irgm3 also 
leads to susceptibility against Toxoplasma gondii [69,70].  However, no consensus has 
been reached on the mechanism by which IRGs confer this resistance. 
One hypothesis describing the mechanism of IRG action involves direct 
modulation of pathogen-containing membranes by IRGs.  Many of the murine GKS 
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IRGs have been shown to converge on the pathogen-containing membranes.  Irga6, 
Irgb6, and Irgd were shown to localize Toxoplasma gondii-containing phagosome; this 
localization was correlated with stripping of the phagocytic membrane, exposing the 
parasite to the cytoplasmic environment and resulting in its death [61].  Irga6 localized 
to this compartment only when it was GTP-bound, implying that it must be activated for 
this localization to occur [71].  In the case of infection with Chlamydia trachomatis (though 
notably not Chlamydia muridarum), Irga6, Irgb6, and Irgd all localized to chlamydial 
inclusion membranes, but instead of stripping the membrane, these proteins appeared to 
target the inclusion to the macroautophagic pathway [72].  Macroautophagy is a 
lysosomal degradation pathway important to innate immunity, and will be discussed 
further in section 1.4.6 of this dissertation. 
Additionally, certain GMS IRGs may also localize to phagosomes and inclusions.  
Upon engagement of a latex bead (which is used as a model pathogen with no defense 
mechanisms) with the phagocytic system, Irgm1 and Irgm3 have been shown to relocate 
to the phagocytic cup of the plasma membrane, and remain associated with the 
maturing phagosome [51,55].   Irgm2 and Irgm3 were additionally found to colocalize to 
Chlamydia trachomatis inclusion membranes [72].  Some controversy exists, however, 
about the ability of GMS IRGs to localize to pathogen-containing compartments.  For 
example, Irgm1 has not been seen on compartments containing certain live pathogens, 
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including Toxoplasma gondii [55,73], Mycobacterium tuberculosis [57], Listeria monocytogenes 
[57], and Chlamydia trachomatis [73]. 
A second hypothesis ascribing a mechanism to IRG-mediated innate immune 
resistance utilizes findings relating the immunity-related GTPases to control of 
macroautophagy, a lysosomal degradative process with innate immune functions, such 
as the above-mentioned targeting of Chlamydial inclusions to lysosomes via this 
pathway.  This hypothesis will be further explored in section 1.4.6 of this dissertation, 
after a discussion of the basic mechanisms of macroautophagy. 
1.2.4.2  The GMS IRGs regulate the GKS IRGs 
Intriguingly, absence of the GKS IRG proteins Irgd or Irga6 in mice results in 
relatively weak susceptibility phenotypes to intracellular pathogens as compared to 
GMS IRG deficiency [55,61,63].  One possible explanation for this difference is the 
previously mentioned finding that the p-loop sequence difference of GMS IRGs leads to 
its members being largely GTP-bound, and thus perpetually activated or in a “ready” 
state, whereas GKS IRGs are preferentially GDP-bound and thus are largely inactive.  
This hypothesis assumes, however, that IRGs play a largely redundant role in resistance, 
and thus the constitutively active forms play a greater role.  Evidence contrary to this 
supposition, however, was demonstrated previously by our lab and others, all of whom 
found that the GMS IRGS have the ability to regulate the expression, localization, and 
activation of GKS IRG proteins [60,62,64].  For instance, in Irgm1- and Irgm3-deficient 
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cells, Irga6 and Irgb6 form large aggregate-like structures, decreasing their localization 
to pathogen-containing compartments [60,62].  This aggregation appears to largely 
consist of GTP-bound protein, raising the question of whether GMS IRGs prevent 
premature activation of GKS IRGs [62].  This ability of GMS IRGs to regulate GKS IRGs 
was further supported by yeast two-hybrid studies and GST-pulldowns which indicated 
direct interactions between GMS and GKS IRGs [62].  Additionally, a recent paper 
indicates that GMS IRGs collect on “self” membranous compartments, but not pathogen-
containing vacuoles, and block the localization of GKS IRGs to these compartments [73].  
Taken together, these findings have led to a model of IRG protein function in which 
GMS IRGs initially interact with and hold inactive the GKS IRGs, until direct infection of 
the cell; infection which triggers GKS IRG release and activation, trafficking specifically 
to the pathogen-containing vacuole (which does not contain GMS IRGs), and subsequent 
modulation of this membrane to promote immune functions. 
In summary, the immunity-related GTPase protein family is a conserved family 
found throughout vertebrate species that plays an important role in interferon-induced 
innate immunity to pathogenic intracellular microbes.  The GMS subfamily of IRGs 
contains a p-loop sequence difference which leads its members to be largely active; their 
functions appear to involve regulation of the typically inactive GKS IRGs.  The specific 
functions of these proteins in innate immunity include modulation of pathogen-
containing membranes and/or regulation of membrane trafficking processes such as 
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macroautophagy.  Further research is necessary to fully determine all the mechanisms 
whereby this family enables innate immunity. 
1.3 Guanylate-binding proteins 
1.3.1  Genetic and proteomic features of the GBP family 
A second family of GTPases which are induced by interferon-γ are the 
guanylate-binding proteins, or GBPs.  Genes with at least 40% identity with a canonical 
GBP (in Mus musculus) have been found in a wide variety of vertebrate species, from 
zebrafish to primates, and the genomes of most species encode multiple GBPs [74-76].  
These proteins have been studied most extensively in mice and humans.  In Mus 
musculus, there are eleven GBP genes clustered on two chromosomes [74,77]; all of these 
proteins have ISREs and/or GAS elements near their promoters [74] and are induced 
very strongly by interferon signaling, and some are additionally induced by IL-1β and 
TNF-α [40,78-80].  In Homo sapiens, there are six GBPs and one GBP pseudogene in a 
cluster on chromosome 1, but similarly to the IRG family in humans, not all of these 
genes have ISREs or GAS elements upstream, indicating that several of these genes are 
likely not interferon-inducible [74].  Unlike the IRGs, guanylate-binding proteins have 
not been subdivided into subfamilies, and thus are named only with the root name Gbp 
and a number.  It should be noted that the numbers assigned to genes do not necessarily 
correlate between species; thus, murine Gbp1 and human Gbp1 should not be assumed 
to be orthologues. 
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The crystal structure of human Gbp1 has been solved, and reveals a protein 
structure that resembles that of IRGs, minus the N-terminal helical domain [81].  In 
GBPs, a globular N-terminal G domain is followed by a C-terminal helical domain, 
although the helices are generally longer than those found in IRGs [81].  The G domain 
is very unique in several ways.  Firstly, the domain lacks a N(T)KXD motif, which is 
typically required for specificity to guanine nucleotide binding, as opposed to adenosine 
nucleotide binding; nevertheless, the G domain appears to bind exclusively to guanine 
nucleotides, and does not bind or hydrolyze ATP, UTP, or CTP [82,83].  Additionally, 
the G domain of GBPs binds with nearly equal affinity to GTP, GDP, and GMP [82], and 
is the only known G domain which can catalyze hydrolysis of GTP to GMP [83].  
Furthermore, a crystal structure of Gbp1 bound to a non-hydrolyzable GTP analogue 
reveals a unique GTP-binding site structure that prevents access of other proteins to the 
bound GTP, preventing the possibility of GAP-protein-induced hydrolysis [84].  Despite 
this extensive knowledge of the uniqueness of the G domain structure of GBPs, 
however, the effects of this uniqueness on GBP protein function are unknown.   
Like the IRGs, GBPs contain motifs which indicate likely associations with 
membranes, including amphipathic helices [81,85] and lipid modification sites such as 
C-terminal isoprenylation motifs (CaaX) [81,85-87].  However, the exact localization sites 
of guanylate-binding proteins are not well elucidated.  Several human GBPs, including 
human Gbp1, Gbp3, and Gbp5, and murine Gbp1, appear to be evenly distributed 
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throughout the cytoplasm [88,89]; the human GBPs Gbp2 and Gbp4 are localized to the 
nucleus in addition to the cytoplasm [88].  Other GBPs, including the murine Gbp2, 
appear to localize to cytoplasmic vesicles of unknown origin or function [89].  However,  
activation of the human GBPs Gbp1 and Gbp2 via aluminum fluoride treatment leads to 
the relocalization of these proteins to the Golgi apparatus [87,88], indicating that 
activation of GBPs leads to their relocalization, which may affect their functions.  
Additionally, human Gbp1 is able to attract Gbp2 and Gbp5 to the Golgi in a 
heterodimerization-dependent manner [86], indicating that membrane-associated GBPs 
can induce membrane association of others via complex formation. 
1.3.2  The GBPs in innate immunity 
The IRG family, as described previously, exhibits antimicrobial activity only 
towards bacteria and protozoa; no known anti-viral properties of these proteins have 
been described.  In contrast, the GBP family is important to direct, cell-autonomous 
innate immunity against bacteria, protozoa, and viruses.  Additionally, specific GBPs are 
important in assembly and function of inflammasomes, which promote inflammatory 
cytokine secretion and induce pyroptosis.  We will briefly describe the role of GBPs in 
each of these three innate immune functions, with particular emphasis on their anti-
bacterial roles, as this function has the most relevance to the work discussed in this 
dissertation. 
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One of the first functions ascribed to GBPs was a role in anti-viral activity.  Both 
human and murine GBPs have demonstrated anti-viral activity against vesicular 
stomatitis virus and encephalomyocarditis virus [90,91].  Additionally, recent studies 
have ascribed antiviral properties to human GBPs in response to hepatitis C [92] and 
influenza [93].  Exact mechanisms of the anti-viral properties of GBPs are only beginning 
to be understood, but they appear to vary depending on the particular viral challenge 
based on differing needs for functional GTP hydrolysis [90-93].  Further work is 
necessary to determine exactly what role GBPs play in innate immunity against viruses. 
More recent studies have discovered potent anti-microbial activities exhibited by 
GBPs in response to a variety of bacteria.  Four seminal studies were particularly 
important to ascertaining the nature of these responses.  The first study, in addition to 
identifying a number of murine GBPs, demonstrated that Gbp1, Gbp2, Gbp3, Gbp5, 
Gbp7, and Gbp9 colocalized with Toxoplasma gondii-containing vacuoles, but not 
vacuoles containing a highly virulent strain; this study was the first to identify a possible 
anti-microbial role for the GBP family [77].  In the second study, it was demonstrated 
that human Gbp1 and Gbp2 localize to Chlamydia trachomatis inclusions and, alone, 
inhibit their growth in a small but statistically significant manner; however, they have a 
greatly increased negative effect on Chlamydia proliferation in the presence of the rest of 
the interferon-γ-mediated response, indicating that GBPs likely work with other 
interferon-induced proteins to mediate innate immunity [94].  The third study involved 
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loss-of-function screens against each member of the murine GBP family, utilizing 
siRNA, dominant-negative mutations, and chromosomal deletion techniques, to 
determine which are important to defend against Listeria monocytogenes and/or 
Mycobacterium bovis (Mb BCG) [85].  The researchers found that Gbp1, Gbp5, Gbp6, 
Gbp7, and Gbp10 were all necessary to control growth of these bacterial species in 
macrophage-like cell lines [85].  The authors further demonstrated that Gbp1, Gbp3, 
Gbp7, and Gbp10 localized to pathogen-containing compartments via association with 
small vesicles which then fused with the pathogen-containing compartment [85].  They 
additionally showed that Gbp7 is important for assembly of NADPH oxidase, which 
generates superoxide species involved in the killing of pathogenic bacteria, and that 
Gbp1 and Gbp7 may be involved in macroautophagy [85], which will be discussed 
further in section 1.4.6 of this dissertation.  Finally, the authors of the fourth study 
generated mice deficient for all five GBP genes found on the murine chromosome three, 
including Gbp1, Gbp2 (which has two splice forms), Gbp3, Gbp5, and Gbp7 [95].  They 
demonstrated that these mice were highly susceptible to Toxoplasma gondii infection, and 
that reintroduction of Gbp1, Gbp5, or Gbp7 partially restored wild-type resistance [95].  
Additionally, they showed that in the absence of these GBPs, Irgb6 was unable to be 
recruited to Toxoplasma gondii-containing vacuoles, indicating an interplay between these 
two families in innate immunity [95].  Together, these four studies indicate important 
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anti-microbial roles for certain members of the guanylate-binding protein family, and 
link them to other proteins induced by interferon-γ signaling. 
In addition to their roles in innate immunity to viral and bacterial/parasitic 
challenges, a role has been established for specific guanylate-binding proteins in 
mediating the NLRP3 inflammasome response.  This inflammasome stimulates the 
activity of caspase-1, which cleaves the inactive forms of the inflammatory cytokines IL-
1β and IL-18 to their active forms and additionally stimulates pyroptosis [96].  A recent 
study indicated that both human and murine Gbp5 promoted the assembly of the 
NLRP3 inflammasome, and thus caspase-1 and IL-1β/IL-18 activity [97].  Intriguingly, 
Gbp5 only promoted this activity in response to certain microbes or microbial 
components, but not to non-biological agonists or adjuvants, revealing novel specificity 
in NLRP3 inflammasome regulation [97].  Additional research is currently being done to 
address the roles of Gbp5 in regulating other inflammasome activities (Pilla and Cöers, 
presentation). 
In summary, the guanylate-binding protein family is a conserved family found 
throughout vertebrate species that plays an important role in innate immunity to 
bacteria, parasites, and viruses.  Their specific functions, though known to be varied, are 
only just beginning to be fully elucidated; these involve cell-autonomous functions such 
as superoxide generation and macroautophagy, and induction of inflammatory 
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responses via inflammasome signaling.  Further research is necessary to fully determine 
all the mechanisms whereby this family enables innate immunity. 
1.4 Macroautophagy 
1.4.1  The importance of degradative processes 
The  breakdown of excess, unnecessary, and/or defective cellular components 
into their basic  parts is a necessary process for homeostasis.  Changing conditions 
within the cell require the creation of different protein networks to maintain appropriate 
physiological conditions, which requires that previous protein networks be degraded 
and recycled.  In the case of nutrient deprivation, when anabolic processes are inhibited 
by a lack of building material, it becomes even more imperative that the cell be able to 
recycle unimportant components to create anabolic building blocks.  Additionally, in 
certain signaling networks, the cell utilizes the rapid breakdown of signal-transducing 
elements to either prevent the premature activation of a response pathway or 
downregulate an active response.  And finally, proteins and organelles which have been 
damaged by various cellular stressors need to be cleared before they develop toxic 
characteristics which are detrimental to cellular function.  Thus, the process of protein 
and organelle degradation is a necessary component to the overall functioning of the 
cell. 
There are two organelles within the cell whose purpose is to degrade cellular 
elements into their component parts:  the proteasome and the lysosome.  It should be 
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noted that the descriptions of proteasomal and lysosomal degradation outlined in the 
following paragraphs are largely focused on their homeostatic functions; however, these 
organelles also participate in processes outside of protein maintenance, for instance, in 
antigen presentation. 
As its name suggests, the proteasome degrades proteins and peptides, and is 
responsible for the majority of protein turnover in the cell [98].  This organelle consists of 
a cylindrical protein core (the 20S subunit) between two regulatory protein subunits (the 
19S regulatory particles) [99].  The 20S core is responsible for proteolysis via threonine- 
and water- dependent nucleophilic attack [100], while the regulatory particles are 
responsible for recognizing proteins tagged for destruction [99].  Because the proteolytic 
core channel of the proteasome is narrow, these regulatory particles also function to 
partially unfold the targeted protein and feed it into the proteolytic interior in an ATP-
dependent manner, a process called translocation [99,101]. 
In order to differentiate those proteins destined for destruction via the 
proteasome, the cell tags the protein with a chain of a small (8.5 kDa) protein called 
ubiquitin.  Ubiquitin is conjugated to proteins via lysine resides or the N-terminal amino 
group; once the first ubiquitin is conjugated, more ubiquitin proteins are conjugated to 
the first to form long ubiquitin chains  [102].  Ubiquitin chains can be of any length, and 
linked through any of its five lysines or N-terminus, with each linkage conferring a 
unique chain conformation; for example, K48-linked ubiquitin chains form are tightly 
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compact globules, whereas K63-linked chains adopt a looser, “beads-on-a-string” 
conformation [102].  Chains can be homogenous in linkage type, consist of several 
different linkages, or even include multiple branched chains, leading to millions of 
possible ubiquitin-derived signals, each conferring a different fate on its substrate [102].  
Not all types of ubiquitin chains lead to degradation of the tagged protein; some can 
affect localization, signaling pathways, or enzymatic function [102].  The ubiquitin signal 
which signals proteasomal degradation nearly always consists of a polyubiquitin chain 
in which ubiquitins are ligated through lysine 48 [103] (although it should be noted that 
some proteins can be degraded by the proteasome in a ubiquitin-independent fashion 
[104,105]). 
Importantly, the proteasome is a protein-based organelle, and thus the size of the 
catalytic channel is fixed.  Cellular components which cannot fit inside the proteasomal 
core are not able to be broken down by this organelle.  In contrast, the lysosome is a 
membranous compartment within the cell, meaning it can fuse with other membranous 
compartments, including other lysosomes, in order to increase in size to accommodate 
large structures destined for degradation.  Lysosomes maintain an acidic interior 
environment (approximately pH 5) via proton pumps and chloride ion channels in order 
to maintain conditions necessary for the function of the approximately sixty degradative 
enzymes found in the lysosomal lumen which can digest any biological macromolecule, 
including nucleic acids, lipids, polypeptides, and carbohydrates (note that the lysosomal 
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membrane is protected from these digestive enzymes by a thick glycocalyx) [106].  Thus, 
while the proteasome is a delicate and controlled degradative organelle specifically 
designed for cleaving designated peptide bonds, the lysosome is a powerful and multi-
functional garbage disposal site for the cell, capable of handling large volumes of 
cellular junk of varied composition.  Additionally, in the event of proteasomal inhibition 
or blockage, the lysosome can serve as a compensatory degradation system 
[107].Because of the formidable degradative internal environment of the lysosome, the 
cell must carefully safeguard the integrity of the compartment while ensuring that 
targeted macromolecules can reach the lumen.  The process of transferring cellular 
components to the interior of the lysosome is referred to as autophagy, or self-eating.  
There are several types of autophagy.  The first, microautophagy, involves the 
invagination of the lysosomal membrane around a portion of cytoplasm, much the same 
as phagocytosis, followed by vesicle scission into the lysosomal lumen (reviewed in 
[108]).  A second type of autophagy, chaperone-mediated autophagy, involves the 
recognition of soluble substrate proteins by chaperones, which then shuttle the unfolded 
protein directly across the lysosomal membrane via specific lysosomal channel proteins 
(reviewed in [109]).  (Note that this is the only form of autophagy which does not 
require the formation of a vesicle to transfer components to the interior of the lysosome.)  
Neither microautophagy nor chaperone-mediated autophagy are important to the work 
presented in this presentation, and thus will not be discussed in further detail.  
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Consequently, we will turn to a detailed examination of the third type of autophagy, 
called macroautophagy. 
1.4.2  Macroautophagy 
In contrast to micro- and chaperone-mediated autophagy, which are responsible 
for the degradation of small, specific substrates, macroautophagy is responsible for bulk 
degradation of cellular components.  It involves the formation of a double-membraned 
vesicle around a portion of the cytoplasm, which can contain whole organelles, large 
protein aggregates, long-lived proteins, or other random cellular components.  This 
vesicle, termed an autophagosome, is then trafficked to and fuses with lysosomes in a 
process called maturation, delivering its contents to the degradative lysosomal 
environment.  The terms macroautophagy and autophagy are often used 
interchangeably, and this process will be referred to by both names for the remainder of 
this dissertation. 
The molecular machinery that regulates autophagosome formation, cargo 
selection, and maturation can be divided into three groups:  the upstream autophagic 
signallers, the core autophagic machinery, and selective autophagy adaptors, each of 
which we will discuss in further detail in the next sections.  Though much of the work 
done to elucidate the autophagosomal machinery was performed in yeast, we will focus 
on what is known of mammalian autophagy because it is the most relevant to the work 
presented in this dissertation. 
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1.4.3  Upstream regulation of macroautophagy 
The process of macroautophagy occurs constitutively at low levels to ensure 
turnover of long-lived proteins and organelles and safeguard proper homeostasis of the 
cytoplasmic environment.  However, levels of autophagy can be modulated in response 
to a diverse array of cellular conditions, including starvation, infection, growth factor 
signaling, DNA damage, and apoptotic processes.  Because of this variety, the signaling 
pathways which modulate levels of macroautophagy are numerous and extremely 
complex, and the interplays between pathways are only just beginning to be 
understood.  The pathways which are described below are diagrammed in Figure 1, 
which is very helpful for understanding the complex systems of activation and 
repression that eventually lead to control of autophagy. 
The “gateway” to control of mammalian autophagy levels is a protein called 
mammalian target of rapamycin, or mTOR [32,33].  This serine/threonine kinase exists in 
two separate protein complexes, one of which, mTORC1, serves as an inhibitor of 
autophagy by causing the phosphorylation and thus inactivation of the autophagy-
initiating ULK complex [110-112].  Signaling pathways which modulate levels of 
autophagy within the cell nearly all modify mTORC1 functioning as their endpoint.  
mTORC1 is itself activated by the small GTPase Rheb in its active, GTP-bound state 
[113]; Rheb is inhibited by its GAP (GTPase activating factor) called the TSC1/TSC2 
complex [31,113-116]. 
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Figure 1:  Select macroautophagy signaling pathways upstream of mTOR.  
mTOR complex 1 (mTORC1) promotes growth pathways while repressing 
macroautophagy.  The activity of this complex is promoted by activated Rheb, and 
repressed by Rheb’s GAP, the TSC1/2 complex.  This complex can in turn be inhibited by 
growth factors, or promoted by energy depletion.  * represents signaling initiation 
points.  See text for further details. 
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One of the better-known stressors which upregulates autophagy is starvation-
induced nutrient deficiency and reduction in energy levels.  One pathway through 
which autophagy is upregulated in response to starvation is mediated by AMP kinase 
(AMPK).  When the ratio of AMP to ATP increases as a result of energy depletion, the 
kinase LKB1 is activated, which phosphorylates and activates AMPK [117-119].  AMPK 
in turn phosphorylates and activates the TSC1/2 complex [120], leading to 
destabilization of Rheb-GTP, inactivation of mTOR, and upregulation of autophagy.  
Other pathways are also known to upregulate autophagy through AMPK; for example, 
an increasing free calcium ion concentration in the cytoplasm also activates AMPK and 
thus autophagy [121], as does the protein p53 in response to DNA damage [122]. 
In contrast, a signaling cascade which eventually inhibits macroautophagy is 
initiated by growth factors such as insulin.  Receptor tyrosine-kinases, upon receiving 
the proper growth factor signal, auto-phosphorylate and activate two separate signaling 
pathways, mediated via class I PI3 kinases [30] or Ras GTPases [123], respectively.  PI3 
kinases activate protein kinase B (PKB, also called Akt), which in turn inhibits the 
tuberous sclerosis complexes (TSC1/TSC2) [31].  Separately, the Ras GTPases, once 
activated by the receptor tyrosine-kinases and in addition to promoting the activity of 
class I PI3 kinases [124], activate the Raf-1/MEK/ERK signaling cascade which also 
inhibits the TSC1/2 complex [125].  Inhibiting TSC1/2 by these two separate pathways 
then stabilizes Rheb-GTP and activates mTOR, thus inhibiting the autophagic process. 
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1.4.4  Core autophagic machinery 
While the pathways which modulate levels of autophagy in the cell are 
numerous and varied, the core autophagic initiation, growth, and maturation machinery 
remains the same.  Figure 2 diagrams the most important members of the basal 
autophagic machinery.  Note that many of the core autophagy proteins have the stem 
name Atg, short for autophagy; former nomenclature referred to them as Apg proteins, 
though this is no longer in use. 
The initiatory complex which is necessary to begin the process of autophagy in 
mammalian systems is called the unc-51-like kinase (ULK) complex.  This complex 
consists of the scaffold FIP200 protein bound to both mAtg13 and one (or more) of the 
three mammalian ULKs [112,126-128]; a possible fourth member of the complex, Atg101, 
has also been described [129].  Interactions with the kinase complex mTORC1, the 
master repressor of autophagy, lead to a series of phosphorylations of various members 
of this complex, which represses its function; in the presence of signals promoting 
autophagy, however, mTORC1 dissociates from the ULK complex, and a separate series 
of phosphorylations promotes its function [112,127].  The overall role of this initatory 
complex is currently unclear, although its existence is necessary for initiation of 
autophagosome formation [126-129]. 
Once autophagosome formation has been initiated, a series of proteins assemble 
together at the phagophore assembly site, or PAS.  The location of this site in mammals 
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appears to be near the endoplasmic reticulum [130,131].  The source of the membranes 
used to build the autophagosome is currently debated, but likely includes ER-derived 
membrane along with de novo membrane synthesis [130-133].  One complex of proteins 
recruited to the PAS is the class III PI3K complex.  The core of this complex consists of 
the class III PI3 kinase hVps34, Beclin-1, and p150, which then associate competitively 
with either Atg14L/Barkor or UVRAG [134-138].  Atg14L is thought to direct localization 
of the complex to the PAS [134,135,137,138].  UVRAG, on the other hand, is thought to 
recruit Bif-1, a protein which has the ability to bend membranes and which may initiate 
the formation of the autophagosomal membrane [139,140].  Intriguingly, the UVRAG-
bound complex also appears to be involved in autophagosome-lysosome fusion, both 
positively (when interacting with HOPS proteins [141]) and negatively (when 
interacting with Rubicon [137,138]), and thus may play a role in both initiation and 
maturation of autophagosomes. 
A second protein complex targeted to the PAS involves a family of orthologues 
of the yeast protein Atg8, of which in mammalian cells there are eight members.  This 
includes four proteins of the microtubule-associated protein 1A/1B-light chain 3 family, 
more commonly called LC3 proteins (A-C, including two splice forms of LC3A), and 
four GABARAP proteins (GABARAP and GABARAPL1-3).  All of these proteins have 
been shown to decorate autophagosomal membranes [136,142].  While the exact roles of 
each member of the Atg8 family in mammals have yet to be elucidated, all of these 
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Figure 2:  Core macroautophagic machinery.  The ULK complex (green), class III 
PI3K complex (purple), Atg16L1 complex (yellow, brown, and fuschia), and LC3 (red) 
all play key roles in the process of macroautophagy.  See text for further details. 
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members are necessary to autophagosome formation [142], and all have been found on 
pathogen-containing autophagosomes [143].  The LC3 proteins are the best studied Atg8 
orthologues, and are often used as models of Atg8 orthologue functioning.  LC3 proteins 
must first be proteolytically cleaved and lipidated before they can be incorporated into 
autophagosomes [144,145]; thus, a complex of LC3-processing proteins also assembles at 
the PAS [146,147].  To begin the progression of LC3-processing, the protease Atg4B 
cleaves the C-terminal residue of pro-LC3 to form LC3-I [148,149].  Next, a large 
complex called the Atg16L complex forms in order to lipidate the newly-exposed C-
terminal glycine of LC3-I.  To create the Atg16L complex, Atg7 (an E1-like enzyme [150]) 
and Atg10 (an E2-like enzyme [151]) facilitate conjugation of the proteins Atg5 and 
Atg12, which interact with Atg16L and then oligomerize [152,153].  This complex then 
conjugates LC3-I to phosphatidylethanolamine (PE), utilizing both Atg7 (the E1-like 
enzyme) and Atg3 (which acts as an E2-like enzyme) [154-156].  Intriguingly, this 
conjugated form of LC3, LC3-II, also appears necessary to the formation of the Atg5-12 
complex, underlying the complexity of this dual-conjugation system [157].  LC3-II is 
integrated into both the outer and inner autophagosomal membranes, and is thought to 
effect closure of the autophagosomal membrane [157-159].  LC3-II is recycled off the 
outer membrane of the autophagosome via cleavage of the lipid bond by the protease 
Atg4B, forming LC3-I which can be reused in autophagosome synthesis [148].  Note that 
GABARAPs are also cleaved and lipidated using the same machinery [145,149,154,160-
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162], but are believed to have a separate role from LC3 proteins in the genesis of 
autophagosomes [142]. 
Two other proteins, mAtg9 and vacuole membrane protein 1 (VMP1), are both 
integral to autophagic initiation in a manner which is poorly understood.  Both are 
transmembrane proteins; mAtg9 may be involved in trafficking membrane to the PAS 
[163,164], while VMP1 may interact with Beclin-1 and/or other members of the class III 
PI3K complex [165,166]. 
Once the autophagosome has been fully formed, it is trafficked to late endosomes 
and/or lysosomes, with which it fuses to form a compartment often called the 
autophagolysosome [167,168].  This process, while not well studied, is known to involve 
Rab GTPases [169] and SNARE proteins [170,171], much like other types of vesicle 
fusion events.  Upon fusion, the inner autophagosomal membrane is broken down by 
lysosomal lipases, including Atg15 in yeast [172,173] (the mammalian system has not 
been studied).  The contents of the autophagosome are thus exposed to the degradative 
interior of the lysosome.  Little is known about how the resultant macromolecules are 
released to the cytoplasm, although the  lysosomal translocator LYAAT-1 has been 
identified as being responsible for some peptide translocation out of the lysosome [174]. 
1.4.5  Selective autophagy 
Macroautophagy has often been thought of as a largely non-specific process; that 
is, the contents of the autophagosome are random, and the process is upregulated in 
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order to provide a stressed cell with abundant anabolic substrates from which to mount 
a response [175].  A more contemporary view has emerged in recent years to encompass 
the discovery that certain proteins and organelles can be specifically targeted to the 
autophagic machinery [176-178].  Certain patterns of ubiquitination, usually K48-linked 
ubiquitin chains, target proteins for proteasomal destruction [102]; however, a different 
set of ubiquitylation patterns are recognized by a category of adaptor proteins recently 
termed “sequestosome-like receptors,” or SLRs [177].  These adaptor proteins also 
interact with the protein LC3 found in the membrane of the forming autophagosome, 
thus physically bringing specific targets to the forming autophagosome to be included in 
its cargo destined for degradation [176-178].  To effect binding of both LC3 and 
ubiquitin, the C-terminal region of SLR adaptor proteins contains two protein-protein 
interaction domains: an LC3-interacting region (LIR) and a ubiquitin-binding domain. 
The four best-studied SLR adaptor proteins are p62/SQSTM1, NBR1, NDP52, and 
optineurin. Of these, p62, NBR1, and optineurin all contain a canonical LC3-interacting 
sequence [179-181].  These LIR domains are short, approximately  twelve amino acids 
long, and possess several key structural features, including a series of acidic residues 
leading up to a key aromatic residue and a later hydrophobic residue (leucine, 
isoleucine, or valine); this structural sequence fits in a hydrophobic pocket of Atg8-
family proteins [178,179].  The LIR domains of p62, NBR1, and optineurin bind to all 
eight members of the Atg8 orthologue family in mammals [179-182], indicating that 
 37 
these SLRs undergo promiscuous binding to forming autophagosomes.  It should be 
noted that a second non-canonical “LIR” region of NBR1 was determined to bind LC3 in 
in vitro studies, although it does not seem to play a role in LC3 interactions in vivo [179]. 
On the other hand, the LIR domain of NDP52 is non-canonical in both structure 
and function.  This sequence does not contain an aromatic residue, but rather relies on a 
Leu-Val-Val sequence that binds only to LC3C, and not other Atg8 family members 
[143].  It remains to be seen whether or not this specific binding to only one Atg8 family 
member is an accident resulting from convergent evolution, or if a functional reason for 
this specificity exists.  One possible explanation for the specificity of the NDP52-LC3C 
interation is that the two subfamilies of Atg8 proteins (LC3 proteins and GABARAP 
proteins) are thought to have differing roles in autophagosome biogenesis and thus may 
be present on autophagic membranes at distinct time points [142]. It is possible that 
NDP52’s unique role in pathogen recognition and signaling requires recruitment at a 
specific step in autophagosome formation.  More research is needed into the exact roles 
of each Atg8 family member before the reason for the NDP52-LC3C specific interaction 
can be deduced. 
The second interaction region important to the autophagy adaptor function of 
SLRs is the ubiquitin-binding domain.  This domain must be able to recognize only 
those ubiquitin chain signals which specifically target a protein to macroautophagic 
degradation.  It is currently unclear, however, which types of ubiquitin signals are used 
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to signify that a target should be degraded by autophagy.  Ubiquitin chains can be of 
any length, and linked through any of its five lysines, with each linkage conferring a 
unique chain conformation; for example, K48-linked ubiquitin chains form are tightly 
compact globules, whereas K63-linked chains adopt a looser, “beads-on-a-string” 
conformation [102].  Chains can be homogenous in linkage type, consist of several 
different linkages, or even include multiple branched chains, leading to millions of 
possible ubiquitin-derived signals, each conferring a different fate on its substrate [102].  
Since it is well established that SLR adaptors target ubiquitinated targets to the 
autophagic pathway, determining what types of ubiquitin chains are recognized by 
various SLR proteins can give insight into which ubiquitin signals select a target for 
macroautophagic degradation. 
There are two categories of ubiquitin-sensing domains found in the SLR adaptors 
dicussed here:  the UBA domain and the UBAN + zinc-finger domain.  p62 and NBR1 
both share a UBA ubiquitin-binding domain.  p62’s UBA domain is specific for K63-
linked ubiquitin chains [183], whereas the UBA domain of NBR1 seems to have its 
highest affinity for di-ubiquitin chains, and has only a slightly higher affinity for K63-
linked di-ubiquitin than for K48-linked di-ubiquitin [184].  This disparity in recognized 
ubiquitin signals for two proteins with a similar function indicates that there is a great 
deal of complexity involved in the discernment of cellular fate through ubiquitin 
tagging, and there are likely many ubiquitin chain conformations that can lead to 
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autophagic degradation.  It remains to be seen whether a specific ubiquitin tag, such as a 
K63-linked chain, is sufficient to target a substrate to the autophagy pathway, or if the 
context of the ubiquitin-substrate complex is necessary to properly recognize the 
ubiquitin tag. 
Less work has been done on the ubiquitin-binding patterns of NDP52 and 
optineurin, which contain a zinc-finger domain (NDP52) or both a zinc-finger and 
UBAN domain (optineurin) to sense ubiquitin.  NDP52’s zinc-finger domain has been 
confirmed to bind to mono-ubiquitin, but has not yet been tested for ubiquitin chain 
binding [185].  Optineurin binds linear tetra ubiquitin, but not mono-ubiquitin or 
ubiquitin-related proteins [181].  These findings are further evidence of the complexity 
of the macroautophagic targeting system. 
While not being specifically relevant to the work presented in this dissertation, it 
is worth mentioning that, in addition to their functions as adaptors of specific 
autophagy, SLRs play a role in upregulating innate immune signaling pathways.  The 
N-termini of the four adaptor proteins discussed here all contain a series of protein-
protein interaction domains associated either with upstream regulators of NF-kB (p62 
and NBR1) or an unidentified TBK1-dependent antimicrobial pathway (NDP52 and 
optineurin) [181,185-189].  This dual-function nature of SLR adaptor proteins as specific 
autophagy mediators and innate immune signalers may imply that SLR adaptors bridge 
the gap between an immediate, cell-autonomous response to cytosolic bacteria 
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(autophagy) and upregulation of inflammatory responses to prevent further cellular 
invasion.  More work is needed in this area to determine if this hypothesis is true. 
1.4.6  The IRG family and the GBP family as mediators of 
macroautophagy 
As outlined in the above sections, macroautophagy is a process of bulk 
degradation which is upregulated by stressors which require a catabolic response, such 
as nutrient deprivation, energy depletion, or DNA damage, and downregulated when 
conditions signal the need for anabolic processes, especially by growth factor signaling.  
Research on macroautophagy thus largely focused on its metabolic consequences, until a 
pivotal paper published in 2004 which introduced a major new function for 
macroautophagic processes.  In this paper, the authors built upon the previous finding 
that Mycobacterium tuberculosis prevents fusion of its phagocytic compartment with 
lysosomes by specifically disrupting an hVPS34-dependent trafficking pathway and 
other PI3P-dependent signaling [190].  Noting that hVPS34 is a PI3K vital to the 
initiation of macroautophagy, as outlined previously in this dissertation, the researchers 
wondered whether this degradative process is responsible for the maturation of 
phagosomes.  They treated mouse macrophage-like RAW 264.7 cells infected with 
Mycobacterium tuberculosis with rapamycin, a compound which upregulates autophagy 
by binding and inhibiting the mTORC1 complex; this treatment overcame the block on 
phagosomal maturation introduced by the bacteria, led the compartments to gain 
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macroautophagic markers such as LC3, and led to successful repression of bacterial 
growth [191].  This was the first paper demonstrating that macroautophagy has anti-
microbial functions.  Additionally, the authors demonstrated that treating these 
macrophage-like cells, which expressed an exogenous GFP-LC3 construct, with the 
cytokine interferon-γ led to the formation of GFP-LC3 puncta, implying that interferon-
γ is able to upregulate macroautophagy as a defense mechanism to promote phagosome 
maturation and bacterial clearance [191].  And finally, the authors went on to claim that 
this macroautophagic response to interferon-γ is mediated by the protein Irgm1, an 
immunity-related GTPase of the M subfamily induced by interferons, by demonstrating 
that overexpression of a GFP-tagged version of Irgm1 led to the formation of large, 
acidic compartments which partially overlapped with LC3, and that this overexpression 
further increased maturation of M. tuberculosis-containing compartments [191].  This 
final observation, that Irgm1 may upregulate macroautophagy, was surprising given 
that no previous evidence had linked interferon-induced GTPases to macroautophagic 
processes, save the knowledge that wild-type Irgm1 localizes to endolysosomal 
compartments and mature lysosomes, a localization which requires a functional G 
domain [56]. 
The researchers soon followed up on these observations, and published a second 
study containing evidence that not only does GFP-tagged Irgm1 overexpression lead to 
the accumulation of acidic compartments, but that it also leads to an accumulation of 
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double-membraned compartments, which is a hallmark of autophagosomes, and to an 
increase in the amount of the lipidated form of LC3, LC3-II [41].  Furthermore, siRNAs 
against Irgm1 repressed the increase in GFP-LC3 puncta exhibited by interferon-treated 
cells, further supporting the notion that Irgm1 drives macroautophagy.  Additional 
research by other groups linked the putative role that Irgm1 plays in driving autophagy 
to the previously observed interferon-γ-induced cell death of certain cell types, 
including demonstrating that Irgm1 protects CD4+ T-lymphocytes from cell death 
induced by IFN-γ in an autophagy-dependent manner [192], and that localization of 
Irgm1 to lysosomes promotes autophagy-related necrotic cell death of hepatocytes [58].  
Other research has linked Irgm1 to driving autophagy in neurons [193]. 
Intriguingly, despite the truncated nature of human IRGM as compared to 
Irgm1, there is some evidence that human IRGM is also a modulator of autophagy.  Two 
studies directly tested the ability of IRGM to affect macroautophagy, and found that 
IRGM siRNA blocked conversion of LC3-I to LC3-II, led to fewer GFP-LC3 puncta upon 
induction of autophagy, and led to defects in the maturation and clearance of 
Mycobacteria-containing [41] or Salmonella typhimurium-containing [194] compartments.  
Additionally, it has been shown that IRGM promotes macrophagic uptake of pathogenic 
adherent-invasive Escherichia coli in the intestines [195].  Other more circumstantial 
evidence involves the finding that certain IRGM SNPs  lead to an increased 
susceptibility to Crohn’s disease, an inflammatory disease of the digestive tract, and that 
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the main intestinal pathology associated with these SNPs is a defect in the granules of 
Paneth cells, immune cells of the intestinal crypt which secrete anti-microbial effectors 
into the intestinal lumen [194,196-198].  These same defects are also seen in patients with 
disease-associated SNPs in the core autophagy gene ATG16L1 [199,200], leading to the 
hypothesis that both ATG16L1 and IRGM are essential for the macroautophagic 
processing of Paneth cell granules.  Intriguingly, similar Paneth cell abnormalities have 
been observed in Irgm1-deficient mice with induced intestinal inflammation, providing 
evidence of a role for murine Irgm1 in the same granule processing [201]. 
While there is much evidence in the literature that Irgm1 and IRGM are 
promoters of macroautophagy, some controversy does exist, as recent developments 
have called this putative function into question.  First, it was recently demonstrated that 
GFP-tagging of Irgm1 (whether N- or C- terminal) leads to loss of Golgi localization in 
favor of endolysosomal localization, likely due to constitutive activation as loss of GTP-
binding ability returned Irgm1 to the Golgi [56].  This finding casts doubt on the 
findings of previous experiments which utilized GFP-tagged Irgm1 to demonstrate 
increases in autophagic markers and colocalization with phagocytic compartments.  The 
authors soon followed up with a paper demonstrating that endogenous Irgm1, in 
contrast to previous findings utilizing GFP-tagged Irgm1, does not colocalize directly 
with mycobacterial or listerial phagosomes [57].  Additionally, a second research group 
examined which of the interferon signaling cascade components were necessary to 
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mediate the induction of macroautophagy in response to interferon-γ [202].  They found 
that while JAK1/JAK2 kinases, the first step in the canonical interferon-γ signaling 
pathway, were necessary to this upregulation, the next step in the canonical pathway, 
activation of STAT-1, was dispensable [202].  Instead, autophagy upregulation in 
response to interferon-γ is mediated by a novel pathway that involves PI3K and p38 
MAPK [202].  Characterization of this novel interferon-γ-induced signaling pathway 
was furthered by another group, which found that interferon-induced macroautophagy 
requires the C/EBP-β transcription factor binding to GATE elements, a pathway which 
does not involve STAT proteins [37].  Because the canonical STAT-1 signaling pathway 
is presumed necessary to Irgm1 expression (due to STAT-1’s importance to innate 
immune responses to bacteria [203] and its necessity for other IRGs’ innate immune 
functions [70]), the authors of the first paper then examined whether Irgm1 was 
necessary to the upregulation of autophagy in response to interferon-γ in macrophages, 
and found a normal macroautophagic response in Irgm1-deficient cells [202].  And to 
add further to the controversy, a recent study found that Crohn’s disease patients 
displayed Paneth cells which constitutively upregulate autophagy, regardless of the 
presence of disease-associated SNPs in ATG16L1 or IRGM, and that this upregulation is 
what leads to Paneth granule defects, rather than an autophagic defect caused by loss of 
ATG16L1 or IRGM [204].  Thus, evidence exists both for and against the notion that 
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Irgm1 and IRGM are mediators of cytokine-induced autophagy, and more research is 
needed in this area to fully examine this hypothesis. 
In addition to a possible role for immunity-related GTPases in regulating 
macroautophagy, studies have examined the role of the guanylate-binding proteins in 
modulating this process.  In one study, it was found that murine Gbp1 interacts directly 
with the specific autophagy adaptor protein p62 outside of its ubiquitin-binding 
domain; additionally, Gbp1 colocalized with LC3 puncta, and its absence led to defects 
in p62 degradation, indicating a block in autophagic maturation [85].  Additionally, 
murine Gbp7 was found to bind to Atg4b, the protease responsible for cleaving pro-LC3 
to its lipidatable state and for LC3 recycling; in the absence of Gbp7, defects in 
autophagosome membrane closure were observed, consistent with an inability of LC3 to 
incorporate into autophagosomal membranes [85].  The authors propose that, since 
Gbp7 was found to bind equally well to both active and inactive Atg4b, Gbp7 is a 
membrane-trafficking protein which delivers antimicrobial effectors, including 
autophagic machinery, to the appropriate intracellular sites [85].  Thus, two of the 
guanylate-binding proteins have been linked to the autophagic system.  More work is 
needed to determine if other GBPs play a role in this degradative process. 
1.5 Motivation for this work 
In this chapter, we have outlined research which establishes interferon-induced 
GTPases, including the immunity-related GTPases (IRGs) and the guanylate-binding 
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proteins (GBPs), as major effectors of the interferon-induced innate immune response.  
These proteins have been demonstrated to control the growth of intracellular 
membrane-bound pathogens through processes which involve membrane modulation.  
These processes can include direct effects on pathogen-containing membranes, as well as 
regulatory roles of membrane-trafficking processes which ultimately deliver anti-
microbial effectors. 
Yet while much research has been done to elucidate the mechanisms of 
interferon-induced GTPase action, several important questions remain to be definitively 
answered.  The first, and most important, question arises from the knowledge that the 
GMS subfamily of IRGs exerts a regulatory function over other subfamilies of IRGs, 
affecting their expression and localization; yet, in the absence of GMS IRGs, there exists 
an almost complete deficiency of interferon-γ-induced host resistance to certain 
pathogens, a deficiency which is not found in the absence of GKS IRGs.  These data 
strongly imply an additional role(s) for GMS IRGs in innate immunity outside of the 
regulation of GKS IRGs.  Additionally, certain species (such as primates) encode GMS 
IRGs but no innate-immune related GKS IRGs, which is further indication that GMS 
IRGs do more than regulate other IRGs.  This additional role played by GMS IRGs in 
innate immunity may include their possible involvement in macroautophagy, as 
outlined previously.  However, contradictory data both supporting and disputing this 
putative function exist, and more work is needed to fully elucidate whether or not GMS 
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IRGs play a direct role in the regulation of macroautophagy.  If GMS IRGs do not affect 
macroautophagy, it is possible that they exert regulatory effects over other effector 
families induced by interferons; one possible candidate for regulation is the guanylate-
binding protein family, which is induced by the same cytokines, belongs to the same 
superfamily of dynamin-related membrane modulators, and displays anti-microbial 
activity toward many of the same micro-organisms.  There are currently no known 
interactions between these two protein families, leaving this possibility to be explored.  
On a related note, several of the guanylate-binding proteins have also been implicated in 
macroautophagic processes, but the roles of many members of this family have yet to be 
investigated. 
In this work, we have further studied the varied roles of two interferon-induced 
GTPase families, the IRGs and the GBPs, in the innate immune response.  We have 
focused particularly on the regulatory roles of GMS IRGs on overall interferon-induced 
immunity.  These findings will provide further insight into the mechanisms of cell-
autonomous innate immunity, with the ultimate goal of discovering novel therapeutic 
interventions which will promote public health.
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2. The GMS IRG subfamily influences the localization of 
Gbp2 by modulating macroautophagy 
[Note: this chapter contains research and excerpted text which was originally published 
in the Journal of Biological Chemistry :  Traver MK, Henry SC, Cantillana V, Oliver T, 
Hunn JP, Howard JC, Beer S, Pfeffer K, Coers J, Taylor GA.  Immunity-related GTPase M 
(IRGM) proteins influence the localization of guanylate-binding protein 2 (GBP2) by 
modulating macroautophagy. J Biol Chem. 2011; 286(35):30471-80.  © the American 
Society for Biochemistry and Molecular Biology.] 
2.1 Introduction 
The innate immune system is comprised of multiple effector pathways that are 
induced in host cells by pro-inflammatory cytokines such as interferon-γ.  Such effectors 
confer on the host cells the ability to more easily eradicate invading pathogens through 
diverse mechanisms.  A prominent family of IFN-γ-induced proteins that are required 
for resistance to intracellular bacteria and protozoa are the immunity-related GTPases, 
or IRGs. 
IRG proteins can be separated into subfamilies based on homology across the 
GTP-binding domain.  Proteins in the M subfamily (often called the GMS IRGs) are 
distinguished from the other proteins by possessing a non-canonical GMS sequence in 
the first GTP-binding motif (G1), while the remaining subfamilies all possess the 
canonical GKS sequence.  Previous work from our lab and others has demonstrated that 
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GMS IRGs play a particularly important role in innate immune resistance to intracellular 
bacteria and protozoa in mice, as described further in chapter 1 of this dissertation.  This 
importance is thought to stem from the ability of GMS IRGs to regulate the localization, 
expression, and function of the GKS IRGs.  And yet, this limited regulatory function 
does not explain the apparent complete absence of IFN-γ-induced host resistance that 
has been noted against several different pathogens as a result of GMS IRG deficiency, 
nor does it explain why certain species, including chimpanzees and humans, express 
GMS IRGs but do not encode innate-immune related GKS IRGs.  An open question, 
therefore, is whether GMS IRGs possess broader regulatory functions over other 
interferon-induced innate immune effector families. 
In this chapter, we address the possibility of broader regulatory functions of 
GMS IRGs by examining whether these proteins can affect the localization and 
functioning of another important family of IFN-γ-induced effectors, the guanylate-
binding proteins (GBPs).  Like the IRG proteins, GBPs can be functionally classified 
within the dynamin protein superfamily and have been implicated in vacuolar 
processing and resistance to pathogens such as Toxoplasma gondii, Listeria monocytogenes, 
and Chlamydia trachomatis.  Despite no previous evidence of interactions between these 
two protein families, we find that the absence of GMS IRGs has striking effects on the 
localization of GBPs.  Our findings suggest that GMS IRG proteins may have activities 
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that extend beyond the IRG protein family to influence other IFN-γ-induced effectors by 
modulating macroautophagy. 
2.2 Results 
2.2.1 Altered localization of Gbp2 in the absence of GMS IRGs 
We and others have previously demonstrated that the GMS IRG proteins Irgm1 and 
Irgm3 regulate the localization of GKS IRG proteins; absence of either leads to the 
relocalization of Irga6 and Irgb6 from the ER and cytosol [51] into aggregate-like 
complexes [60,62].  We chose to address whether absence of the GMS IRGs has similar 
effects on other interferon-regulated innate immune effectors.  We found that absence of 
Irgm1 or Irgm3 in interferon-treated mouse fibroblasts or macrophages grossly altered 
distribution of the interferon-induced protein Gbp2.  Gbp2 is a member of the 
guanylate-binding protein family, a little-studied interferon-induced family of proteins 
with some similarities to the immunity-related GTPases, as outlined further in chapter 1 
of this dissertation.  In the absence of GMS IRGs, we found that the localization of Gbp2 
changed from punctate cytoplasmic structures – presumably small vesicles to which 
Gbp2 has been purported to localize in previous studies [89] – to much larger, 
aggregate-like structures (Figure 3).  A hollow core was apparent in most of the Gbp2- 
positive structures, (Figure 3, arrows), particularly in deconvolved images, suggesting 
that they might be membranous/vesicular, although this structural feature might also be 
a result of an artifact introduced by deconvolution.  These structures strongly resemble  
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Figure 3:  Altered localization of Gbp2 in the absence of GMS IRGs.  A)  3T3  
MEFs or primary BMM of the indicated genotypes were treated with 100 U/mL IFNγ for 
24h.  Cells were then processed for immunofluorescence with αGbp2 antibody.  
Representative of three trials.  Arrows denote puncta displaying a ring-like structure.  B)  
3T3  Irgm1-deficient MEFs were treated with 100 U/mL IFNγ for 24h, then processed for 
immunofluorescence with αGbp2 antibody.  Z-stack images were obtained (left panel, 
one plane), then deconvolved (right panel, one plane).  Representative of three trials.  
Arrows denote puncta displaying a ring-like structure. 
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those formed by Irga6 and Irgb6 in the absence of GMS IRGs, implying a similar 
regulatory mechanism of GMS IRGs over guanylate binding proteins. 
2.2.2 Gbp2 colocalizes with GKS IRGs in the absence of GMS IRGs 
Because of the strong resemblance between aggregate-like structures formed by 
GKS IRGs and Gbp2 in the absence of GMS IRGs, we next chose to determine whether 
GKS IRG proteins were concurrently present in the Gbp2-positive compartments.  Co-
staining studies demonstrated that nearly all of the Gbp2-positive structures in Irgm1- 
and Irgm3-deficient cells also contained Irga6 (94±2% and 77±9%, respectively) (Figure 
4).  In contrast, Irga6 and Irgb6 colocalized in only a fraction of these structures (38±4% 
in Irgm1-deficient cells and 46±11% in Irgm3-deficient cells), indicating that while these 
structures contained both GBPs and IRG proteins, there was some heterogeneity in 
composition among them.  Collectively, these data suggest that Irgm1 and Irgm3 
regulate processes that control the transfer of GBP and IRG proteins from diverse initial 
locations within the cells to an overlapping set of large, aggregate-like compartments. 
2.2.3 GMS IRG deficiency leads to an accumulation of Gbp2-
containing autophagosomes 
Because of the ring-like nature of the structures containing Gbp2 and GMS IRGs, 
along with the preference of dynamin-like proteins for binding intracellular membranes 
[43,44],  we postulated that these structures were membranous compartments within the 
cell; thus, we attempted to identify the specific compartment with a variety of co-  
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Figure 4:  Gbp2 colocalizes with GKS IRGs in the absence of GMS IRGs.  A)  
3T3  MEFs of the indicated genotypes were treated with 100 U/mL IFNγ for 24h.  Cells 
were then processed for immunofluorescence with the indicated antibodies.  Images are 
two-dimensional projections of z-stacks of the entire volume of the cell.  Representative 
of three trials.  B) The percentage of Irga6 puncta which colocalized with Gbp2 was 
scored in a treatment-blinded fashion in 10 cells per treatment.  Cells with no Irga6 
puncta were not scored.  Differences between populations were not statistically 
significant by Student’s t-test.  C)  3T3  MEFs of the indicated genotypes were treated 
with 100 U/mL IFNγ for 24h.  Cells were then processed for immunofluorescence with 
the indicated antibodies.  Images are two-dimensional projections of z-stacks of the 
entire volume of the cell.  Representative of three trials.  D) The percentage of Irga6 
puncta which colocalized with Irgb6 was scored in a treatment-blinded fashion in 10 
cells per treatment.  Cells with no Irga6 puncta were not scored.  Differences between 
populations were not statistically significant by Student’s t-test. 
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staining studies utilizing markers for intracellular lipid compartments and the 
cytoskeleton.  The Gbp2-positive structures did not colocalize with a number of these 
markers, including TRAP-α (ER), GM130 (Golgi), EEA1 (early endosomes), LAMP1 (late  
endosomes / lysosomes), mitotracker red (mitochondria), bodipy (lipid droplets), actin, 
tubulin, or vimentin (data not shown).  We did find, however, that some (32-42%) of the 
Gbp2-positive structures were positive for LC3, a marker of autophagosomes (Figure 5).  
Macroautophagy (described in detail in chapter 1 of this dissertation) is a system of bulk 
degradation in which a double membrane forms around a portion of the cytoplasm, 
creating an autophagosome that fuses with late endosomes/lysosomes and becomes  
 
 
Figure 5:  Gbp2 colocalizes with autophagosomes.  A) Primary MEFs of the 
indicated genotypes were treated with 100 U/mL IFNγ for 24h.  Cells were then 
processed for immunofluorescence with the indicated antibodies.  Images are two-
dimensional projections of z-stacks of the entire volume of the cell.  Representative of 
three trials.  B)  The percentage of Gbp2 puncta which colocalized with LC3 was scored 
in 2-7 cells per treatment per trial over three trials.  ANOVA did not indicate a 
significant treatment effect. 
 55 
acidified, leading to the degradation of its contents.  In our co-staining studies, it was 
clear that certain Gbp2 aggregate-like structures colocalized with LC3 in GMS IRG-
deficient cells (Figure 5).  Additionally, a similar percentage of the very few Gbp2 
aggregate-like structures found in wild-type cells also colocalized with LC3 (Figure 5). 
While the Gbp2-positive structures found in all genotypes were LC3-positive, they were 
not LAMP1-positive (data not shown), which suggests that these are likely immature or 
abortive autophagosomal structures.  Finally, partial rings that were Gbp2 positive were 
commonly noted in Irgm1-deficient cells, indicating that Gbp2 may be acquired early 
during the process of autophagosome formation (data not shown). 
 
 
Figure 6:  GMS IRG deficiency leads to an increased number of 
autophagosomes.  A) Primary MEFs of the indicated genotypes were treated with 100 
U/mL IFNγ for 24h.  Cells were then processed for immunofluorescence with αLC3 
antibody.  Images are two-dimensional projections of z-stacks of the entire volume of the 
cell.  White arrows denote autophagosomes, defined as puncta which are larger and 
more intense than background puncta.  Representative of three trials.  B)  The number of 
autophagosomes per cell was scored in a treatment-blinded fashion in 10 cells per 
treatment per trial over three trials.  ANOVA indicated a significant treatment effect, p < 
0.01; * significant difference from wild-type, p < 0.05 via Tukey’s HSD test. 
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 Together, the data we have just presented imply that in the absence of GMS 
IRGs, Gbp2 and GKS IRGs localize to aggregate-like structures which are cleared by  
macroautophagy.  Thus, it would be expected that in the absence of GMS IRGs, 
macroautophagy would be upregulated to facilitate the clearance of the increased 
number of protein aggregates, leading to an overall increase in the number of 
autophagosomes in GMS IRG-deficient cells.  To test this, we identified autophagosomes 
in wild-type and GMS IRG-deficient MEFs via LC3 immunostaining.   In IFN-γ-
activated Irgm1- and Irgm3-deficient cells, there was an increase in the number of large, 
intense LC3 puncta per cell relative to activated WT cells (Figure 6), suggesting that 
GMS IRG deficiency does lead to an increase in autophagosome levels. 
 Much of the literature concerned with determining the effects of various 
conditions on autophagosome number utilizes a GFP-LC3 expression construct to 
fluorescently mark autophagosomes and make them amenable to counting.  This use of 
an exogenously expressed construct, however, can introduce artifacts into the results; for 
example, GFP-LC3 has been shown to be attracted to protein aggregates (of which we 
have demonstrated there are many in GMS IRG deficient cells), leading to fluorescent 
puncta which are indistinguishable from true autophagosomes [205,206].  Thus, we felt 
that our use of endogenous LC3 staining to determine autophagosome number in Figure 
6 was a better choice; however, few articles in the literature utilize this method of 
autophagosome counting, and so we decided to compare endogenous LC3 staining and 
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GFP-LC3 expression in determining autophagosome number in GMS IRG-deficient cells.  
First, we compared the overall number of GFP puncta in GFP-LC3 expressing cells to the 
number of large, endogenous LC3 puncta in untransfected cells (Figure 7, A+C).  As we 
found in our first experiment, the number of large, endogenous LC3 puncta significantly 
increased in Irgm1-deficient cells in an interferon-dependent manner.  [It should be 
noted that it is unfeasible to count all endogenous LC3 puncta because of the technical 
difficulty in distinguishing small puncta from background, thus the reason for counting 
only large, intense puncta (for example endogenous LC3 staining, see Figure 6)].  In 
comparison, the number of GFP puncta in GFP-LC3-transfected cells exceeded the 
number of endogenous puncta by a factor of 50-100, which was expected given the 
increased ability to distinguish GFP puncta from background.  However, while the 
absence of Irgm1 did increase the number of LC3 puncta in these cells, this effect was 
not interferon-dependent, and thus was not due to the increase in aggregation of 
interferon-induced proteins found in Irgm1-deficient cells.  The most likely cause for this 
increase, then, is that GFP puncta were counted which were not true autophagosomes, 
thus artificially inflating the number of autophagosomes and masking real effects on 
autophagy; this reasoning is supported by previous data from the literature indicating 1-
2 autophagosomes per cell in GFP-LC3-transfected wild-type cells [41], a number more 
closely resembling the findings of our endogenous LC3 experiments.  Thus, we decided 
to recount the autophagosome number in our GFP-LC3 transfected cells, only counting  
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Figure 7:  A comparison of endogenous vs exogenous LC3 puncta in 
determining autophagosome number in GMS IRG deficient MEFs.  A) 3T3 MEFs of 
the indicated genotypes were nucleofected with a GFP-LC3 expression construct, then 
treated with 100 U/mL IFNγ for 24h.  Cells were then processed for fluorescent 
microscopy.  The number of LC3 puncta per cell was scored in a treatment-blinded 
fashion in 10-20 cells per treatment per trial over three trials. 2x2 ANOVA indicated a 
main effect of genotype, p < 0.02.  B)  3T3 MEFs of the indicated genotypes were 
nucleofected with a GFP-LC3 expression construct, then treated with 100 U/mL IFNγ for 
24h.  Cells were then processed for fluorescent microscopy.  The number of large LC3 
puncta (defined as puncta which are larger and more intense than background puncta) 
per cell was scored in a treatment-blinded fashion in 10-20 cells per treatment per trial 
over three trials. 2x2 ANOVA indicated a main effect of genotype, p < 0.005.  C)  3T3 
MEFs of the indicated genotypes were treated with 100 U/mL IFNγ for 24h.  Cells were 
then processed for immunofluorescence with αLC3 antibody.  The number of large LC3 
puncta (defined as puncta which are larger and more intense than background puncta) 
per cell was scored in a treatment-blinded fashion in 20 cells per treatment per trial over 
three trials. 2x2 ANOVA indicated a significant interaction term, p < 0.05; * p < 0.05 via 
Tukey’s HSD test. 
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the larger, more intense puncta as we did for the endogenous LC3 (Figure 7, B).  This 
time, we found a similar number of autophagosomes per cell as in endogenous cells, 
along with a similar pattern of interferon-dependent autophagosome increase in Irgm1-
deficient cells; this increase was just short of significance, p < 0.07.  In summary, we 
conclude that the number of autophagosomes in Irgm1-deficient cells, when properly 
counted, increases in an interferon-dependent manner, consistent with the hypothesis 
that autophagy is upregulated to degrade the protein aggregates caused by GMS IRG 
deficiency. 
Importantly, previous studies have shown that Irgm1 may drive autophagosome 
initiation; for example, overexpression of Irgm1 in RAW 264.7 cells led to an increased 
number of autophagosomes, while knock-down of  Irgm1 expression led to a decrease in 
IFN-γ-induced autophagosome number [41].  However, the data we have just presented 
indicate that autophagy is also induced in the absence of GMS IRG proteins.  This 
seeming contradiction could be explained by a hypothetical twofold function of GMS 
IRGs: firstly, to upregulate autophagy as a mechanism to remove intracellular 
pathogens, and secondly, to prevent premature activation and aggregation of GKS IRGs 
and GBPs.  Thus, the presence of Irgm1 may drive autophagy, but in its absence, 
autophagy may additionally be upregulated to degrade the resultant GKS IRG/GBP 
aggregates.  It should additionally be noted that considerable controversy over whether 
Irgm1 is a driver of autophagy exists in the literature, as described further in chapter 1 of 
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this dissertation, casting doubt on whether this contradiction does exist.  Further 
research into the role of Irgm1 in macroautophagy is needed, and will be addressed in 
chapter 3 of this dissertation. 
2.2.4 Gbp2 colocalizes with ubiquitin and p62 in the absence of GMS 
IRGs 
There are several mechanisms through which proteins may enter the autophagic 
pathway for degradation.  One of these involves ubiquitination of targeted proteins, 
followed by their transfer to the autophagic system by an adapter protein called 
p62/Sqstm1.  This protein binds both ubiquitin and the autophagosome outer membrane 
component LC3, physically bringing polyubiquitinated molecules to the forming 
autophagosome, with p62 eventually being degraded along with the other contents of 
the autophagosome [180,182].  Additionally, p62 has been determined to be important 
not only for the clearance of aggregates, but for the initial formation of aggregate 
inclusions [207].  To determine whether p62 plays a role in the clearance of the Gbp2- 
and GKS IRG- containing aggregate structures through autophagy, we first performed 
costaining with anti-ubiquitin and anti-p62 antibodies, revealing that the Gbp2-positive 
structures (Figure 8) and Irga6-positive structures (data not shown) seen in the absence 
of Irgm1 or Irgm3 are also positive for ubiquitin and p62, providing further evidence 
that these aggregate structures are targeted to the macroautophagic pathway. 
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Figure 8:  Gbp2 colocalizes with p62 and ubiquitin in the absence of GMS 
IRGs.  A) Primary MEFs of the indicated genotypes were treated with 100 U/mL IFNγ 
for 24h.  Cells were then processed for immunofluorescence with the indicated 
antibodies.  Images are two-dimensional projections of z-stacks of the entire volume of 
the cell.  Representative of three trials.  B) The percentage of Gbp2 puncta which 
colocalized with p62 was scored in a treatment-blinded fashion in 10 cells per treatment.  
Cells with no Gbp2 puncta were not scored.  Differences between populations were not 
statistically significant by Student’s t-test.  C) Primary MEFs of the indicated genotypes 
were treated with 100 U/mL IFNγ for 24h.  Cells were then processed for 
immunofluorescence with the indicated antibodies.  Images are two-dimensional 
projections of z-stacks of the entire volume of the cell.  Representative of three trials.   
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2.2.5 GMS IRG deficiency leads to increased levels of K63-linked-
ubiquitinated proteins 
Polyubiquitin chains can be linked through any of seven lysines in the ubiquitin 
sequence, leading to chains with unique three-dimensional structures and characteristics 
[208].  It has recently been shown that unlike the commonly studied K48-linked 
polyubiquitin chains, K63-linked polyubiquitinated proteins are largely insensitive to 
degradation by the proteasome [209].  Furthermore, depolarized mitochondria are 
decorated with K63- and K27-linked polyubiquitin chains, leading to selective 
autophagy of these organelles [210].  Additionally, the ubiquitin-binding domain of the 
selective autophagy adaptor protein p62 is specific to K63-linked ubiquitin chains [183].  
Together, these results imply that K63- and K27-linked polyubiquitin tags may be 
signals for selective quality control autophagy.  In the current studies, we utilized TUBE 
1, a peptide designed to stabilize and identify polyubiquitinated proteins and which has 
approximately a ten-fold higher affinity for K63-linked polyubiquitin chains over K48-
linked chains, to examine levels of polyubiquitinated protein in GMS IRG deficient cells.  
Total levels of TUBE1-precipitated proteins, which may be enriched for K63-linked 
polyubiquitinated proteins, were increased in Irgm1- and Irgm3-deficient cells (Figure 
9), indicating that there was an increase in formation and/or a block in removal of at 
least some ubiquitinated proteins in these cells, consistent with the idea that GMS IRG 
proteins could be required for normal autophagic clearance of GKS IRG proteins. 
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Figure 9:  GMS IRG deficiency leads to increased levels of K63-linked-
ubiquitinated proteins.  Primary MEFs of the indicated genotypes were treated with 
100 U/mL IFNγ for 24h, then lysed.  Poly-Lys-63-ubiquitinated proteins were 
precipitated from these lysates using TUBE1-conjugated resin.  Resultant proteins were 
examined via western analysis using αFK2 (conjugated ubiquitin) antibody.  This study 
was done by Stanley Henry. 
 
2.2.6 IRGM deficiency leads to an increase in K63-linked 
ubiquitination of Irga6, but not Gbp2 
We next studied whether TUBE1 could specifically precipitate certain proteins 
found in the aggregates formed in the absence of Irgm1, which would indicate that these 
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proteins are polyubiquitinated, likely through K63 linkages, and thus might be targeted 
to macroautophagic degradation.   TUBE 1 was able to precipitate protein species 
recognized by anti-Irga6 antiserum that were of higher molecular weight than Irga6, and 
likely represent ubiquitinated Irga6 (Figure 10).  Apparent in the samples derived from 
Irgm1- and Irgm3-deficient cells was a ladder/smear that is typical of proteins in 
ubiquitin-positive inclusions [211], suggesting an increase in K63-linked 
polyubiqutinated Irga6 in those cells.  This finding thus implies that GKS IRG proteins 
form polyubiquitinated aggregates that are transferred via p62/Sqstm1 to the autophagic 
system for degradation. 
 
 
Figure 10:  GMS IRG deficiency leads to an increase in K63-linked-
ubiquitination of Irga6, but not Gbp2.  Primary MEFs of the indicated genotypes were 
treated with 100 U/mL IFNγ for 24h, then lysed.  Poly-Lys-63-ubiquitinated proteins 
were precipitated from these lysates using TUBE1-conjugated resin.  Resultant proteins 
were examined via western analysis using αIrga6 (left) or αGbp2 (right) antibodies.  
Representative of three trials.  This study was done by Stanley Henry. 
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We also addressed whether Gbp2 was ubiquitinated using the TUBE 1 pulldown 
assay (Figure 10).  In contrast to the results examining Irga6, no high molecular weight 
species identified by Gbp2 antibodies were found in the TUBE 1 pulldowns, suggesting 
that Gbp2 is not substantially K63-ubiquitinated in wild-type, Irgm1-deficient, or Irgm3-
deficient cells, although an additional treatment with the autophagy inhibitor 
wortmannin would confirm that ubiquitinated Gbp2 is not simply degraded at an 
accelerated rate.  Furthermore, this finding suggests that Gbp2 is not itself a degradative 
target of autophagy, and thus might be found in autophagosomal structures because it is 
a part of the autophagic machinery.  This hypothesis will be examined further in chapter 
4 of this dissertation. 
2.3 Discussion 
In this chapter, we have presented evidence that in the absence of GMS IRG 
proteins, Gbp2 and the GKS IRGs Irga6 and Irgb6 form aggregate-like structures of a 
heterogeneous composition.  It should be noted that these structures are not classic 
aggresomes, as they lack several important features: classic aggresomes are typically 
surrounded by a vimentin cage [212], whereas this cage is lacking in the Irgm1/3-
regulated structures; classic aggresomes are localized near the microtubule organizing 
center of the cells [212], whereas the Irgm1/3-regulated structures do not demonstrate 
this restricted localization; and classic aggresomes occur at one per cell [212], whereas 
several of the Irgm1/m3-regulated structures were often found in a single cell.  Next, we 
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demonstrated that these structures colocalize with LC3, ubiquitin, and p62, which 
together are markers of specific autophagy.  We established that the formation of these 
aggregates is accompanied by an overall increase in autophagosome number.  And 
finally, we showed that GMS IRG deficiency alters K63-linked polyubiquitination of 
Irga6, but not Gbp2.  From these data, we propose the following model for autophagic 
maintenance of GKS IRG protein levels in wild-type cells.  GKS IRG proteins are held in 
an inactive state by direct interactions with GMS IRGs, as proposed previously [62].  
Excess GKS IRGs aggregate, a process that likely occurs continuously at a low level, as 
we found that approximately 10% of wild-type MEFs contain at least one Irga6- and 
Gbp2-positive aggregate-like structure (data not shown).  These aggregates are 
recognized by unknown factors, and are then polyubiquitinated through K63 linkages.  
Polyubiquitinated aggregates are recognized and consolidated into aggregate inclusions 
by p62/Sqstm1, colocalize with Gbp2, and are brought to autophagosomes, where they 
are degraded. 
While the model we have proposed explains many of the observations we have 
made, there is an alternative model through which these data could be interpreted.  We 
have proposed that the increase in autophagosome number found in the absence of GMS 
IRGs is due to an increase in autophagosome formation to degrade an increased number 
of protein aggregate inclusions.  A second possible explanation for this increase in 
autophagosome number, however, is that GMS IRGs are directly involved in increasing 
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the maturation of autophagosomes, such that in their absence an accumulation of 
immature autophagosomes would occur.  In fact, several lines of data we and others 
have produced support this hypothesis.  First, while the aggregate-like structures we 
have characterized are both LC3 and p62 positive, indicating that they are 
autophagosomal compartments, they are LAMP-1-negative, demonstrating that they 
have not yet fused with lysosomes.  Second, many of the LC3-positive structures we 
found appeared abnormally large, a feature which may indicate autophagosome-
autophagosome fusion which can occur when autophagic maturation is blocked [213].  
And third, a previous study indicated that Irgm1 is able to directly interact with Snapin, 
a part of the SNARE complex whose primary function is to enable vesicle docking, 
including autophagosome-lysosome fusion [170,171,214].  Together, these data suggest 
that GMS IRGs may play a role in regulating autophagosome maturation, a hypothesis 
we will explore further in chapter 3 of this dissertation. 
One question raised by the data presented in this chapter concerns the clear 
distinction between the way in which GMS IRG proteins affect Gbp2 and GKS IRG 
proteins.  The latter, represented by Irga6 in our studies, are likely ubiquitinated 
through K63 linkages, as suggested by the TUBE 1 pull down studies. In absence of 
Irgm1 or Irgm3, the amount of ubiquitinated Irga6 that accumulates in cells increases 
substantially, possibly due to lack of efficient removal through Irgm1/3-driven 
autophagy.  In contrast, our studies suggest that there is little K63-linked-ubiquitinated 
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Gbp2 in IFN-γ-activated cells, whether wild-type or lacking Irgm1 or Irgm3.  These 
findings raise the question of whether GMS IRGs are directly regulating the localization 
of Gbp2, leading to it being targeted for degradation by autophagy in the absence of 
GMS IRGs, or whether instead Gbp2 is recruited to autophagosomes in GMS-IRG-
deficient cells as a protein that is involved in the autophagic process itself.  This latter 
hypothesis is supported by previous studies indicating a role for certain guanylate-
binding proteins in macroautophagy, including direct interactions between Gbp1 and 
p62, and evidence that Gbp7 colocalizes with LC3 and affects the rate of p62 degradation 
[85].  We will examine the relationship between the guanylate-binding proteins and 
autophagy further in chapter 4 of this dissertation. 
We have described here data which indicate a role for the GMS IRGs in 
regulating the formation of protein aggregate structures which are cleared by 
macroautophagy.  The work presented in the next chapters will provide additional 
descriptive details about the nature of these aggregates, and clarify the mechanisms 
whereby GMS IRGs and GBPs affect macroautophagy.  Our ultimate goal remains to 
determine the importance of this pathway in cell autonomous immune responses to 
intracellular infection. 
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2.4 Materials and methods 
2.4.1 Cell culture 
Irgm1 (LRG-47)-deficient and Irgm3 (IGTP)-deficient mice were generated as 
described previously [215]. The mice were maintained according to Institutional Animal 
Care and Use Committee-approved protocols at the Durham VA and Duke University 
Medical Centers (Durham, NC). Mouse embryonic fibroblasts were derived from these 
mouse lines and immortalized by the standard 3T3 procedure [216].  Atg5-deficient 
fibroblasts were a gift from Herbert Virgin, Washington University, St. Louis, MO. 3T3 
fibroblasts were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS 
(Hyclone, Logan, UT); 10 ug/mL ciprofloxacin was occasionally added to control 
infection. 18-24 hours prior to many experiments (as indicated in the text), 100 units/ml 
IFN-γ (#407320, Calbiochem, EMD Biosciences, San Diego, CA or #IF005, Millipore, 
Billerica, MA) was added to the culture medium. 
Primary BMM were isolated from the tibia and femurs of 2- to 4-month-old mice. 
Bone marrow was flushed from the bones using a 27-gauge needle fitted to a syringe 
filled with DMEM, and the marrow was dispersed by drawing through the needle three 
to four times. Red cells were lysed with ACK lysing buffer (Invitrogen). Adherent cells 
were cultured for 6 days in bone marrow macrophage medium (culture medium 
supplemented with 30% (v/v) L929 cell-conditioned culture medium). The cells were 
cultured on Petri dishes, resulting in cultures that were loosely adherent and easily 
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removed from the plates with cell dissociation buffer (#13150–016, Invitrogen). After day 
6, procedures diverged depending on the experiment. 
2.4.2 Transfection and Nucleofection 
DNA transfections were performed using X-tremeGENE 9 or HP transfection 
reagent (#06365779001, Roche, Pleasanton, CA) according to manufacturer’s instructions.  
Nucleofections were performed using the Amaxa Biosystems Nucleofector II (Lonza, 
Basel, Switzerland), along with nucleofector kit R (#VCA-1001, Lonza), according to 
manufacturer’s instructions.  MEF were nucleofected using program number U-30, and 
BMM were nucleofected using program number Y-1. 
2.4.3 Immunocytochemistry 
Cells were plated on poly-D-lysine-coated (#P7280, Sigma) coverslips and 
subjected to treatment conditions as described in the text.  Cells were then fixed with 4% 
paraformaldehyde (w/v) in PBS for 15 min, rinsed in 100 mM glycine/ PBS for 5 min, and 
permeabilized with 0.2% (w/v) saponin/PBS for 10 min. Cells were blocked with 10% 
(v/v) FCS/PBS for 60 min. As indicated in the text, the cells were then stained with 
various primary antibodies for 60 min, followed by AlexaFluor-conjugated secondary 
antibodies (Molecular Probes/Invitrogen) for 60 min. Primary antibodies used include 
anti-Irga6 mouse monoclonal clone 10E7 antibody [51] at 1:10, anti-Irgb6 rabbit 
polyclonal antiserum [60] at 1:1000, anti-GM130 mouse antibody (#612009, BD 
Transduction Laboratories) at 1:250, anti-TRAPα rabbit polyclonal antiserum (a gift of 
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Chris Nicchitta, Duke University) at 1:125, anti-EEA1 mouse antibody (#610456, BD 
Transduction Laboratories) at 1:25, anti-proteasome 20S C2 rabbit polyclonal antiserum 
(#ab3325, Abcam, Inc.) at 1:500, anti-p62/Sqstm1 rabbit polyclonal antiserum (#ab91526, 
Abcam, Inc.) at 1:500, anti-LC3B mouse monoclonal antibody (#M152–3, MBL 
International, Woburn, MA) at 1:50, phalloidin-conjugated AlexaFluor 488 (Molecular 
Probes/Invitrogen) at 1:40 (no secondary antibody used), anti-Gbp2 rabbit polyclonal 
antiserum [77] at 1:500, or anti-Gbp2 rabbit polyclonal antiserum (Jörn Coers, Duke 
University) at 1:1500 (these two Gbp2 antisera were used interchangeably with 
essentially identical results in all contexts), and anti-mono- and poly- ubiquitin mouse 
monoclonal clone FK2 (#BML-PW8810, Enzo Life Sciences, Farmingdale, NY) at 1:750.  
Images were collected on an Olympus IX70 microscope equipped with a Hamamatsu 
C8484–03G01 digital camera. Cells were magnified x1000. Wide-field fluorescence 
images and z-stacks were collected using Metamorph 6.2.3.5. As mentioned in the text, 
images were, when appropriate, deconvolved using Auto Quant 9.3 software. 
2.4.4 Western blotting 
Western blot analyses were performed according to standard protocols. In brief, 
lysates were boiled in SDS and separated on 8–16% gradient Tris-glycine gels (#EC60485, 
Invitrogen). Proteins were transferred overnight to Immobilon synthetic membranes 
(Millipore). Membranes were blocked in 5% (w/v) milk in TBS-Tween 20 for 60 min, then 
incubated in primary antibody for 60 min, washed, and incubated in secondary antibody 
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for 60 min.  Primary antibodies utilized include anti-Gbp2 rabbit polyclonal antiserum 
(Jörn Coers, Duke University) at 1:1000, anti-Irga6 rabbit polyclonal antiserum 165/3 [51] 
at 1:10000, and anti-mono- and poly- ubiquitin mouse monoclonal clone FK2 (#BML-
PW8810, Enzo Life Sciences, Farmingdale, NY) at 1:500.  Secondary antibodies used 
were goat anti-rabbit (H+L) HRP-conjugated IgG and goat anti-mouse (H+L) HRP-
conjugated IgG (#AP307P and #AP308P, Millipore) at 1:1000. Blots were developed in 
SuperSignal west pico chemiluminescent substrate (#34708, Thermo Scientific, Rockford, 
IL) and imaged on a Kodak Image Station 4000R using Carestream Molecular Imaging 
software. 
Carestream software was used to quantify band intensities.  The “find lanes” 
feature was used, and lanes were adjusted manually as necessary.  The “find bands” 
feature was then used, and extraneous bands were deleted.  The band intensity was 
measured as the sum intensity of the resultant band peak. 
2.4.5 TUBE 1 pull-down of polyubiquitinated protein 
Wild-type, Irgm1-/-, and Irgm3-/- 3T3 cells were grown in 15-cm tissue culture 
dishes and exposed to 100 units/ml IFN-γ for 24 h prior to lysis. Cells were washed in 
PBS and lysed in 0.6 ml of lysis buffer (50mM Tris-HCL (pH 7.4), 0.15 M NaCl, 1mM 
EDTA, 1% Nonidet P-40, 10% glycerol). Input control samples were obtained by 
removing 0.2-ml aliquots and centrifuging at 16,000 x g at 4 °C for 5 min. Supernatants 
were mixed 3:1 with 4x sample buffer containing 0.4 M DTT (Invitrogen). To assay for 
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detergent-insoluble protein aggregates that might sediment during centrifugation, 
pellets were suspended in 0.2 ml of 1x sample buffer containing 0.1 M DTT. Viscosity of 
the pellet suspension was reduced by 10–15 passages through a 23-gauge needle 
attached to a 1-ml syringe. To keep aggregated proteins in the suspension, the lysates 
were not cleared by centrifugation. Agarose beads coupled to tandem ubiquitin binding 
entity 1 (TUBE 1, LifeSensors, Malvern, PA) or uncoupled beads were equilibrated in 
TBS-T (10mM Tris-HCl (pH 8.0), 0.15 M NaCl, 0.05% Tween 20) according to the 
supplier’s recommendations.  A sedimented bead volume of 30 ul was used per pull-
down sample. Lysates were incubated with uncoupled agarose beads for 30 min at 4 °C. 
Beads were sedimented at low speed (700 x g), and the supernates were transferred to 
tubes containing TUBE 1-coupled beads. Incubation at 4 °C was continued for 1 h. Beads 
were sedimented and washed in TBS-T a total of four times.  Beads destined for 
proteomic analysis were stored at 4ºC in 100 uL of storage buffer [PBS, 1:50 Protease 
Inhibitor Cocktail Set III (#539134, Calbiochem), 50 uM DUb inhibitor PR-619 (#SI9619, 
LifeSensors)] until further analysis. 
2.4.6 Data Analysis 
Results are presented as mean ± SE unless otherwise indicated.  Treatment effects 
and/or variable interactions were determined by analysis of variance (ANOVA).  Where 
such effects were found, post-hoc analysis for specific mean comparisons was completed 
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using Tukey’s HSD test.  Significance levels were set at p < 0.05 (95% confidence, two-
tailed) for all analyses. 
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3. The regulation of Irga6 and Irgb6 aggregate formation 
and clearance by Irgm1 
3.1 Introduction 
In chapter 2 of this dissertation, we established that loss of Irgm1 and/or Irgm3 
leads to the formation of protein aggregates containing the GKS IRG proteins Irga6 
and/or Irgb6, as well as the related interferon-induced GTPase Gbp2.  Furthermore, we 
identified markers of specific autophagy in these aggregates, indicating a role for 
macroautophagy in their clearance.  We showed that loss of Irgm1 may have global 
effects on clearance levels of aggregated proteins marked for specific autophagy.  And 
finally, we demonstrated that while Irga6 is marked for specific autophagic clearance, 
Gbp2 is not.  Together, these findings imply that GKS IRG proteins form aggregate 
inclusions which are removed by a macroautophagic process which may be GMS-IRG 
mediated.  In this chapter, we will further explore the regulation of the formation and/or 
clearance of GKS IRG protein aggregate inclusions by GMS IRG proteins. 
Several important questions about this regulation of GKS IRGs by GMS IRGs are 
raised by the findings presented in chapter 2 of this dissertation.  First, while we 
demonstrated that GKS IRG protein aggregates are marked for specific autophagic 
clearance by the p62 adaptor protein, we presented no direct evidence that p62 is 
necessary for this clearance; thus it remains to be answered what role p62 plays in this 
process.  A second unaddressed question is which other of the many GKS IRG proteins 
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form aggregates in the absence of GMS IRG proteins, and whether or not other proteins 
or protein families similarly aggregate in the absence of GMS IRGs.  And finally, the 
exact role of GMS IRG proteins in regulating macroautophagy, if any such exists, has yet 
to be fully determined.  As we mentioned in the previous chapter, our and other labs’ 
data indicate that GMS IRGs may affect autophagy in several ways:  they may drive 
autophagy initiation, as seen in certain experiments indicating an increase in 
autophagosomes when Irgm1 is expressed in cells [41,191]; they may drive 
autophagosome maturation, which would explain the build up of possibly immature 
autophagosomes we found in their absence; and/or they may indirectly affect autophagy 
by preventing the formation of the GKS IRG aggregates that drive autophagy 
upregulation in their absence.  The answers to these questions will further elucidate the 
associations of GMS and GKS IRG proteins with the process of macroautophagy, and 
may provide further insight into their roles in innate immunity. 
In this chapter, we will present evidence to resolve these remaining questions 
surrounding the regulation of aggregate formation and clearance by GMS IRG proteins.  
We will demonstrate that, while absence of the autophagy adaptor protein p62 affects 
Irga6 protein levels, it is surprisingly not necessary for the formation of Irga6 aggregate 
inclusions, nor for their colocalization with LC3.  Next, we will present the findings of 
an unbiased proteomic approach to determine proteins that are destined for specific 
autophagy in the absence of GMS IRG proteins, which indicates that Irga6 and Irgb6 are 
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the only GKS IRG proteins which are tagged in this fashion.  And finally, we will 
examine the role of Irgm1 in the process of macroautophagy, demonstrating mixed 
results that may imply cell-type specific effects of Irgm1 on macroautophagy in 
macrophages, but reveal no effect of Irgm1 on autophagic initiation or maturation in 
fibroblasts.   Together, these findings clarify the uniqueness of the connection between 
Irgm1, Irga6, and Irgb6, and add further evidence of the complex relationship between 
GMS IRGs and macroautophagy. 
3.2 Results 
3.2.1 p62 is not necessary for the formation or clearance of Irga6 
aggregate inclusions 
Given our previous data indicating p62 colocalization with Irga6 protein 
aggregates, we set out to determine whether or not p62 is necessary for Irga6 aggregate 
localization to autophagosomes.  In order to study this, we depleted MEFs of both Irgm1 
(to induce high numbers of GKS IRG protein aggregates) and p62, and then examined 
colocalization of Irga6 with the autophagosomal marker LC3.  We first accomplished 
this double depletion via siRNA temporary knockdown of p62 in Irgm1 knockout MEFs 
to, on average, 12% of wild-type protein levels via western analysis (Figure 11, A-B).  
Surprisingly, Irga6 aggregates in these cells were found to colocalize with LC3 (Figure 
11, C), indicating autophagic clearance of these aggregates even when p62 has been 
largely depleted.  It is possible, however, that the level of p62 knockdown we achieved  
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Figure 11:  p62 deficiency does not affect LC3-Irga6 colocalization.  A) p62 
knock-down (western).  Wild-type 3T3 MEFs were or were not treated with the 
indicated siRNAs for 24h, then were processed for western analysis.  B)  p62 knock-
down (immunofluorescence).  Wild-type 3T3 MEFs were or were not treated with the 
indicated siRNAs overnight, then were treated with 100 U/mL IFNγ for 18h.  Cells were 
then processed for immunofluorescence.  C)  Irgm1-deficient MEFs were treated with 
the indicated siRNAs overnight, then were treated with 100 U/mL IFNγ for 18h.  Cells 
were then processed for immunofluorescence.  Arrowheads indicate colocalization 
between Irga6 and LC3.  D)  p62-deficient MEFs were treated with Irgm1 siRNA 
overnight, then were treated with 100 U/mL IFNγ for 20h.  Cells were then processed for 
immunofluorescence.  Arrowheads indicate colocalization between Irga6 and LC3. 
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was insufficient to completely negate p62 function; thus, we repeated the experiment 
utilizing Cre-adenovirus infected floxed p62 MEFs (p62fl/fl) [217] treated with Irgm1 
siRNA to induce GKS IRG protein aggregation (Figure 11, D).  These cells also exhibited 
colocalization of Irga6 and LC3, indicating that p62 is not necessary to thedegradation of 
GKS IRG protein aggregates.  It is likely, therefore, that while p62 can be involved in 
GKS IRG protein aggregate clearance, a redundant autophagic SLR adaptor protein such 
as NBR1 is also able to aid in the clearance of Irga6 aggregates formed in the absence of 
Irgm1. 
3.2.2 Proteomic analysis of K63-linked ubiquitinated proteins that 
accumulate in Irgm1 knockout cells 
Now that we have further examined the mechanism of clearance of GKS IRG 
protein aggregates by macroautophagy, we turn to another question, that of which (if 
any) other interferon-induced proteins aggregate in a similar fashion to Irga6 and Irgb6 
in the absence of Irgm1.  We chose to base our assessment on which proteins are marked 
for specific autophagy in the same fashion as Irga6 in the absence of Irgm1 – that is, 
which proteins display an increase in lysine-63-linked ubiquitination in Irgm1-deficient 
cells.  We thus performed TUBE1 pull-downs on wild-type and Irgm1-deficient primary 
MEFs to isolate polyubiquitinated proteins, then subjected the resultant supernatant to 
GeLC-MS/MS analysis to identify component proteins (Figure 12).  Proteins which were 
identified in a control resin sample were excluded from further analysis.  The semi-
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quantitative spectral counting method was then applied, which assigns proteins their 
abundance in the sample based on the number of spectra found for each of their  
 
 
Figure 12:  Schematic of Proteomic Analysis of TUBE 1 Pull-Down 
Experimental Design.  A) Three samples were analysed: one control sample, one WT 
MEF lysate pull-down, and one Irgm1KO MEF lysate pull-down.  B) Samples were 
separated on a polyacrylamide gel and visualized via coomassie staining.  Pull-down 
samples were divided into six gel bands to minimize masking effects.  The thick protein 
band in slice 4 corresponds to eluted TUBE 1 protein.  C) Each gel slice was analysed 
separately via GeLC-MS/MS.  D) Resultant spectra were identified by searching against 
the NCBI mouse protein database. Note that proteins found in the control resin sample 
were excluded from further analysis. E) Pull-down samples were compared via the 
semi-quantitative spectral counting method. 
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identified component peptides.  A table of all 137 proteins identified in this proteomic 
screen, along with their estimated fold changes between wild-type and Irgm1 knockout 
samples based on the spectral counting method, can be found in Appendix A of this 
dissertation.  Select proteins of interest identified in the study are summarized in Table 
2. 
A few interesting findings can be reported from the results of this proteomic 
assay.  First, the only GKS IRG proteins pulled down in any sample by TUBE1 are Irga6, 
Irgb6, and Irgb10.  (Note that many murine IRGs, including members of the A,B,C,D, 
and M subfamilies, are found in the NCBI mouse database; however, of the A subfamily, 
only Irga6 is contained in the database, and of the B subfamily, only Irgb5, Irgb6, and 
Irgb10 are represented.)  Of these three proteins pulled down by TUBE1, only Irga6 and 
Irgb6 increased in abundance in the Irgm1 knockout pull-down sample, which correlates 
with the increased number of GKS IRG protein aggregates in Irgm1 knockout cells.  This 
finding implies that Irga6 and Irgb6 may have a special relationship with Irgm1 among 
GKS IRG proteins.  Additionally, Irga6 had one of the highest fold changes of any 
protein in the sample, with an approximately 3.6 fold increase in the Irgm1 knockout 
pull-down sample, indicating a further special relationship between the presence of 
Irgm1 and Irga6 aggregation. 
Interestingly, although all murine GBPs are found in the NCBI mouse database, 
the only guanylate-binding proteins identified in the pull-down samples were Gbp2 and  
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Table 2: Select Proteins Differentially Found in TUBE 1 Pull-Down Samples.  Fold 
change is reported with respect to Irgm1KO; positive fold changes are higher in 
Irgm1KO, while negative fold changes are lower in Irgm1KO.  Fold changes ≥1.5 are 
considered biologically significant and are reported in green (positive) or red (negative). 
Name Reference 
Number 
Peptide 
Count 
Fold 
Change 
Irga6 NP_068564.4 4 3.6 
Irgb6 NP_001138636.1 2 1.5 
Irgb10 NP_001128587.1 1 -1.0 
Gbp2 NP_034390.1 3 1.2 
Gbp6 NP_919317.2 3 -1.5 
p62 NP_035148.1 3 -1.1 
Stat1 NP_001192243.1 1 -2.8 
 
Gbp6.  Gbp6 (but not Gbp2) was identified previously in a screen to determine which 
GBPs were important to cell-autonomous immunity to Mycobacterium bovis (BCG) and/or 
Listeria monocytogenes [85].  This previous screen also identified Gbp1 and Gbp7 as being 
both important to immunity and involved in macroautophagy, Gbp1 as an interactor 
with p62, and Gbp7 as an interactor with the protease Atg4b [85].  The proteomic screen 
reported here did not identify Gbp1 or Gbp7 as being highly ubiquitinated, which 
supports the finding of the previous screen that Gbp1 associates with p62 outside of its 
ubiquitin-binding domain, and that neither of these two proteins are macroautophagic 
cargo proteins [85].  The identification of Gbp6 as being ubiquitinated highlights a 
possible involvement of this protein with macroautophagy which warrants further 
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investigation.  Furthermore, Gbp6 displayed slightly decreased ubiquitination (1.5-fold) 
in the absence of Irgm1, a relationship which should be further explored.   In contrast, 
the abundance of ubiquitinated Gbp2 remained relatively equal between wild-type and 
Irgm1-deficient samples.  This finding that Gbp2 is ubiquitinated differs slightly from 
the TUBE1 pull-down western analysis reported in chapter 2 of this dissertation, in 
which full-length Gbp2 was not identified in TUBE1 pull-down of wild-type or Irgm1 
deficient lysates.  This lack of identification indicates that levels of ubiquitinated Gbp2 
protein are quite low in abundance; alternatively, the identification of Gbp2 in the 
proteomic screen might imply that Gbp2 briefly associates with ubiquitinated proteins 
captured in the pull-down studies.  Importantly, though, Gbp2 abundance does not 
significantly change between wild-type and Irgm1-deficient samples, which indicates 
that the presence of Irgm1 does not affect the relationship between Gbp2 and 
macroautophagy, a finding we will explore further in chapter 4 of this dissertation. 
Finally, the abundance of ubiquitinated Stat1, a member of the interferon family 
signal cascade, decreased significantly in the Irgm1 deficient pull-down sample.  This 
finding may imply that Stat1 is upregulated (ie, not degraded) in the absence of Irgm1.  
It seems more likely, however, that Stat1 is ubiquitinated as a function of its signaling 
capacity, instead of because of a link with specific autophagy [102]; this would imply 
that Stat1 signaling is decreased when the interferon response is confounded by the 
absence of Irgm1, possibly as a mechanism of down-regulating the interferon response 
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to limit toxic effects on the cell.  These hypotheses are worthy of further consideration, 
but such studies must rely on further research into the ubiquitin signaling code. 
It should be noted that this proteomic analysis is a good first step to answer the 
question of which interferon-induced proteins are ubiquitinated in the absence of Irgm1; 
however, due to time and money constraints, only one trial of this assay was able to be 
completed, and thus the results should be examined in that light.  It is very important 
that further experimentation be done to confirm the results reported here, including 
western analysis of TUBE1 pulldown samples utilizing antisera for additional IRG and 
GBP proteins.  These confirmatory studies are currently planned, but were unable to be 
completed before the publication of this dissertation. 
 In summary, the results of the proteomic analysis of TUBE1 pull-downs indicates 
that a special relationship may exist between Irgm1 and the GKS IRG proteins Irga6 and 
Irgb6, leading these two specific proteins to aggregate in Irgm1’s absence.  Furthermore, 
the presence of Irgm1 seems to have little or no effect on ubiquitination of Gbp2, which 
will be explored further in chapter 4 of this dissertation. 
3.2.3 Effects of Irgm1 deficiency on autophagosome maturation 
We have now discussed specific characteristics of the Irga6 and Irgb6 aggregates 
that form in the absence of Irgm1, but we have yet to address the mechanism whereby 
loss of Irgm1 leads to an accumulation of these aggregates.  As we have demonstrated 
that these GKS IRG aggregates colocalize with autophagic markers, we have 
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hypothesized that the formation of these aggregates is related to the process of 
macroautophagy.  GMS IRGs may affect autophagy directly or indirectly.  Direct effects 
may include driving autophagosome initiation, supported by the demonstrated increase 
in autophagosomes when Irgm1 is expressed in cells [41,191], or driving 
autophagosome-lysosome fusion, evidenced by an accumulation of LC3-positive but not 
LAMP-1 positive structures in GMS IRG-deficient cells;  indirect effects may include 
preventing the formation of GKS IRG aggregates which themselves increase autophagy.  
It should be noted that none of these hypotheses are mutually exclusive, and some 
combination of these may be true.  The third of these hypotheses, that GMS IRGs 
directly interact with and thus prevent the premature activation and aggregation of GKS 
IRGs, has been described previously [62]; thus we will focus on the possible direct 
effects of Irgm1 on macroautophagic processes. 
To begin, we will examine whether or not GMS IRGs promote the maturation of 
autophagosomes. 
3.2.3.1 p62 degradation assay 
The first of three assays which we utilized to examine autophagosome 
maturation as a function of Irgm1 is the p62 degradation assay.  As an SLR adaptor 
protein, p62 is reliably degraded by the process of macroautophagy; thus, if 
autophagosome maturation is blocked, p62 will no longer be degraded and will 
accumulate within the cell.  We examined levels of p62 both before and after induction  
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Figure 13:  Irgm1 deficiency does not affect autophagosome maturation (p62 
degradation assay).  A) Sample blot.  Primary MEFs or BMM of the indicated genotypes 
were incubated with or without 100 U/mL IFNγ for 24 hours, then were processed for 
western analysis.  Representative of n = 3 trials.  This experiment was done by Stanley 
Henry.  B) Quantitative analysis of western results.  3T3 transformed MEFs, primary 
MEFs, or BMM of the indicated genotypes were incubated with or without 100 U/mL 
IFNγ for 24 hours, then were processed for western analysis.  Band intensities were 
quantified and normalized to actin levels.  Values are reported as ratios of normalized 
p62 in IFN-treated sample to normalized p62 in untreated sample.  2x3 ANOVA results 
indicated a significant interaction term, p < 0.02 ; this analysis was followed by 1 way 
ANOVA, indicating a significant treatment effect, p < 0.0002.  * p < 0.01 via Tukey’s HSD 
test.  Data represent n = 2-4 trials with 1-2 replicates per trial. 
 
of autophagy by interferon-γ treatment in MEFs, immortalized MEFs, and bone-marrow 
macrophages.  In wild-type cells of both kinds of MEFs, p62 levels decreased as expected 
upon interferon-γ treatment, indicating typical autophagic induction in these cell types 
in response to interferon-γ (Figure 13).  Wild-type BMM, however, exhibited a more 
varied response to interferon, showing either a decrease in p62 (Figure 13, A) or a 
relatively equivalent amount of p62 (Figure 13, B).  The reason for this varied response is 
unclear, as previous studies found that macrophage-like RAW 264.7 cells exhibited an 
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induction of autophagy upon interferon treatment [41,191].  This finding may suggest 
that p62 levels are a poor readout for autophagic activity in bone-marrow-derived 
macrophages, as discussed further at the end of this section. 
Next, we examined changes in p62 levels in Irgm1-deficient cells of all three cell 
types.  In both primary and immortalized MEFs with Irgm1 deficiency, p62 levels 
similarly decreased in response to autophagic induction, indicating normal autophagy 
in these cell types even in the absence of Irgm1 (Figure 13).  In contrast, p62 levels 
increased over 2-fold upon induction of autophagy in Irgm1-deficient BMM; this finding 
could indicate a cell-specific role for Irgm1 in autophagic maturation in macrophages. 
The results of this assay suggest that interferon-γ may have differential effects on 
autophagy as a consequence of cell type, and that Irgm1 may function differently based 
on cellular context.  Past studies have often focused on macrophages and macrophage-
like cells to determine the effects of Irgm1 on autophagy [41,191]; the results of the assay 
presented here, which indicate varied induction of autophagy in macrophages in 
response to interferon-γ, do somewhat contradict the results of those previous studies.  
However, assays utilizing p62 as a marker of autophagic flux have the major caveat that 
p62 has functions outside of macroautophagy.  As described further in chapter 1 of this 
dissertation, p62 also interacts with upstream regulators of NF-kB and has been 
demonstrated to affect levels of inflammatory cytokines such as IL-1β and TNF-α, in 
addition to playing a role in the stress response to reactive oxygen species [187,188,218-
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220].  Thus, other functions of p62 may play a more important role in macrophages than 
in fibroblasts and could account for the differences observed between these two cell 
types.  We therefore conducted studies of autophagic maturation utilizing two other 
assays in both cell types. 
3.2.3.2 GFP-LC3 degradation assay 
The second assay we used to examine autophagosome maturation is the GFP-
LC3 degradation assay.  When exogenously expressed in cells, GFP-LC3 is incorporated 
into autophagosomes; upon acidification of the autophagosomal lumen, the fluorescent 
tag is cleaved from LC3 prior to degradation of both proteins.  Thus, levels of free GFP 
fluctuate in response to changes in the maturation of autophagosomes.  We 
demonstrated that levels of free GFP decrease in cells treated with bafilomycin A1, a 
pharmacological inhibitor of autophagosome-lysosome fusion, in a treatment-time 
dependent manner (Figure 14, A).  We then examined levels of free GFP in wild-type 
and Irgm1-deficient MEFs (Figure 14, B) and BMM (Figure 14, C).  In direct contrast to 
the results we obtained from the p62 degradation assay, we found in both MEFs and 
BMM that levels of free GFP increase in response to Irgm1 deficiency.  This finding 
implies that loss of Irgm1 in either of these cell types does not affect autophagic 
maturation, and in fact leads to an increase in autophagic activity.  An increase in 
autophagy in response to Irgm1 deficiency is consistent with the hypothesis that Irgm1  
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Figure 14:  Irgm1 deficiency does not affect autophagosome maturation (free 
GFP assay).  A) Proof of concept assay.  Wild-type MEFs were nucleofected with GFP-
LC3 and treated with 100 U/mL interferon-γ for 24 hours.  Cells were concurrently 
treated with 100 nM bafilomycin A1 for the indicated lengths of time.  After treatment, 
cells were processed for western analysis.  B) MEFs of the indicated genotypes were 
nucleofected with GFP-LC3 and treated with 100 U/mL interferon-γ and 100 nM 
bafilomycin A1 (where indicated) for 24 hours.  Following treatment, cells were 
processed for western analysis.  Blot is representative of 3 trials.  C) BMM of the 
indicated genotypes were nucleofected with GFP-LC3 and treated with 100 U/mL 
interferon-γ and 100 nM bafilomycin A1 (where indicated) for 24 hours.  Following 
treatment, cells were processed for western analysis.  Blot is representative of 2 trials. 
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affects autophagy indirectly, by preventing the formation of GKS IRG aggregates which 
themselves upregulate autophagy.  However, a cautionary note should be applied to the 
interpretation of these findings, as possible differences in transfection efficiencies 
between genotypes not fully evident in the western blots may have affected the results. 
3.2.3.3 Tandem-fluorescent LC3 assay 
The third and final assay we utilized to examine autophagosome maturation in 
Irgm1-deficient cells is the tandem-fluorescent LC3 assay.  This assay directly measures 
immature autophagosome number by taking advantage of the different sensitivities to 
acidic environments of the fluorescent tags GFP and mCherry.  An LC3 construct that is 
tagged with both GFP and mCherry is expressed in cells and incorporated into forming 
autophagosomes.  Both tags fluoresce in the non-acidic environment of an immature 
autophagosome, causing those structures to fluoresce yellow; upon maturation of the 
autophagosome by lysosome fusion, however, the lumen is acidified, which quenches 
the fluorescence of GFP but not mCherry, and leads mature autophagosomes to 
fluoresce red (Figure 15, A).  Thus, the number of mature and immature 
autophagosomes can be counted separately in individual cells (Figure 15, B).  We 
subjected both primary MEFs and BMM to this analysis, using cells treated with the 
pharmacological maturation blocker bafilomycin A1 as positive controls (Figure 15, C).  
The average percentage of immature autophagosomes in MEFs did not change between 
wild-type and Irgm1-deficient cells, which supports the results of the previous two  
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Figure 15:  Irgm1 deficiency does not affect autophagosome maturation 
(tandem fluorescence assay).  A) Schematic representation of tandem fluorescence 
assay.  Doubly-fluorescent-tagged LC3 is expressed in cells and incorporated into 
forming autophagosomes.  Both tags fluoresce in the non-acidic environment of 
immature autophagosomes, leading to yellow fluorescence.  Once the autophagosome 
matures and is acidified, GFP fluorescence is quenched, leading to red fluorescence.  B)  
Representative image obtained from assay.  After the image is thresholded to remove 
background fluorescence, red and yellow puncta are clearly distinguishable.  C)  Assay 
results.  MEFs were nucleofected with tandem fluorescent LC3 construct and examined 
live with resonant scanning confocal microscopy.  n=3 experiments with 5-10 cells 
imaged per treatment group.  ANOVA indicates a significant treatment effect, p < 0.05;  * 
p < 0.05 via Tukey’s HSD post-hoc analysis.  BMM were nucleofected with tandem 
fluorescent LC3 construct after five days of treatment with CSF.  Cells expressing the 
construct at high levels (1-5% of the population) were sorted by FACS analysis and 
examined live with resonant scanning confocal microscopy.  n=4 trials with 5-10 cells 
imaged per treatment group per trial.  ANOVA indicates a significant treatment effect, p 
< 0.05;  * p < 0.05 via Tukey’s HSD post-hoc analysis. 
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assays indicating no block in autophagic flux in MEFs in the absence of Irgm1.  In bone-
marrow macrophages, a ~15% increase in immature autophagosomes was seen in the 
absence of Irgm1, but this increase was not statistically significant, and additionally was 
far less than the increase seen upon bafilomycin treatment.  We thus conclude that the 
absence of Irgm1 may cause a small, cell-type specific negative effect on autophagic 
maturation, but further study is needed. 
The major caveat to this assay is the technical challenge of ensuring nearly equal 
intensities of the green and red channels in image collection and analysis.  Due to 
technical considerations, the red channel was often less intense, and occasionally  
autophagosomes which fluoresced green (not yellow) were observed, which should not 
be possible given the nature of the experiment.  The presence of these green puncta 
indicates that the red channel was slightly under-collected and that mature (red-
fluorescent) autophagosomes may occasionally have been missed, leading to the likely 
over-estimation of the percentage of immature autophagosomes that we report.  
However, excitation and collection parameters were kept constant for all treatment 
conditions, and thus each condition was affected by this technical issue to the same 
extent, making comparisons between these conditions valid. 
In summary, the results of these three flux assays, taken together, strongly 
indicate that in MEFs, Irgm1 deficiency does not affect the maturation of 
autophagosomes.  However, a small, cell-type dependent effect on autophagosome 
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maturation may exist in bone-marrow macrophages, coupled with a possible increase in 
autophagic initiation (observed in the free GFP assay), likely due to an increased 
number of protein aggregates.  The cell-type dependent nature and small magnitude of 
the observed effect on autophagic flux strongly implies that any effects of Irgm1 on 
autophagosome maturation are indirect, as a result of other consequences of Irgm1 on 
cellular function. 
3.2.4 Effects of Irgm1 overexpression on autophagosome initiation 
Finally, we turn to the question of whether or not Irgm1 may directly promote 
autophagic initiation.  Previous studies demonstrated that overexpression of GFP-
tagged Irgm1 promoted the formation of acidic, double-membraned structures in 
macrophage-like RAW 264.7 cells [41,191].  Given the cell-type dependent effect of 
Irgm1 on autophagosome maturation that we found, we decided to expand the results of 
these previous studies to include MEFs.  We chose to overexpress wild-type Irgm1 in 
MEFs, as opposed to the GFP-Irgm1 construct used in previous studies, because of 
concerns raised previously that the GFP tag may constitutively activate Irgm1 [56].  We 
compared the number of endogenous LC3 puncta in cells expressing Irgm1 to the 
number found in untreated wild-type cells and interferon-treated Irgm1-deficient MEFs 
(Figure 16).  Our results in MEFs did not confirm those of previous experiments in RAW 
264.7 cells; expression of Irgm1 in wild-type cells did not significantly increase the  
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Figure 16:  Overexpression of Irgm1 does not increase autophagosome number.  
3T3 MEFs of the indicated genotypes were or were not nucleofected with an Irgm1 
expression construct, and were or were not treated with IFNγ for 24 hours, then were 
processed for immunofluorescence using αIrgm1 and αLC3 antibodies.  The number of 
LC3 puncta per cell was quantified in a blinded fashion.  ANOVA indicated no 
significant treatment effects.  Data represent n = 2-3 trials with 8-12 cells quantified per 
treatment group per trial. 
 
number of LC3 puncta above that found in untreated wild-type cells.  These conflicting 
results may be due to different methodologies (GFP-tagged vs. wild-type Irgm1, and 
double-membraned structure observance vs endogenous LC3 puncta counting).  
However, given that the results of many assays we have outlined in this chapter are cell-
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type dependent, it seems likely that if Irgm1 has direct effects on autophagy, they are 
cell-type specific, and assays should be interpreted based on their cellular context. 
3.3 Discussion 
In this chapter, we have further characterized the GKS IRG protein aggregates 
that form in the absence of Irgm1.  We have presented evidence that p62 is not necessary 
to the degradation of Irga6 aggregate inclusions, but does have an effect on overall levels 
of Irga6.  We demonstrated via proteomic analysis of K63-linked ubiquitinated proteins 
that Irga6 and Irgb6 may have a special relationship with Irgm1 and may be the only 
GKS IRG proteins to form aggregates in its absence.  We then examined the mechanism 
by which absence of Irgm1 leads to an accumulation of protein aggregates, focusing on 
the effects of Irgm1 on macroautophagy.  We demonstrated that Irgm1 overexpression 
in fibroblasts does not affect autophagic initiation, nor does its absence in fibroblasts 
affect autophagosome maturation; however, a small negative effect on autophagosome 
maturation may occur in macrophages in the absence of Irgm1. 
Our finding that p62 was unnecessary to both the formation of Irga6 aggregate 
inclusions and their colocalization with LC3 was very surprising, given the well-
established role of p62 as a promoter of aggregate inclusion formation and an 
autophagic adaptor.  However, we have proposed that a redundant SLR adaptor protein 
is able in the absence of p62 to mediate the transfer of Irga6 aggregates to autophagic 
compartments.  We were unable to determine if the SLR adaptor NBR1, which has many 
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structural similarities to p62, also localized to Irga6 aggregates due to technical issues 
with antibody visualization by immunofluorescence (data not shown); we hope that 
future advances in SLR research will provide the tools to definitively answer whether 
other SLR adaptors provide a redundant function to p62 in this context. 
The results of the proteomic analysis of TUBE1 pulldown samples, implying that 
Irga6 and Irgb6 are the only GKS IRGs which are K63-linked ubiquitinated, suggest that 
these two GKS IRGs are the only ones with a relationship to the macroautophagic 
system.  A previous study indicated a role for macroautophagy in targeting Irga6 to 
pathogen-containing vacuoles [221], but no evidence has previously linked Irgb6 to 
macroautophagy.  Additionally, our results imply that Irga6 and Irgb6 have a different 
relationship with Irgm1 than other GKS IRGs.  Previous models of GMS IRG function 
proposed that this subfamily interacts with all GKS IRGs to prevent their premature 
activation [62].  However, our data indicate that Irga6 and Irgb6 behave differently than 
other IRGs in the absence of Irgm1; it remains to be seen whether this difference is a 
result of characteristics inherent to Irga6 and Irgb6, or inherent to the relationship 
between Irgm1 and these IRGs. 
Finally, our experimental results describing the effects of Irgm1 on 
macroautophagy lend further complexity to the already thorny debate over whether 
GMS IRGs mediate interferon-induced macroautophagy.  Our data indicate that effects 
of Irgm1 on macroautophagy vary based on cell type, and argue against a direct role of 
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Irgm1 in autophagosome initiation or maturation in MEFs, while reaching somewhat 
inconclusive results in BMM.  Furthermore, the results of the GFP-LC3 degradation 
assay indicating an increase in autophagosome activity in the absence of Irgm1 support 
the hypothesis proposed previously that Irgm1 indirectly affects autophagy by 
preventing the premature activation (and aggregation) of its effector proteins Irga6 and 
Irgb6 [62].  Further research is still needed to ascertain any direct effects Irgm1 may have 
on macroautophagy in macrophages, and the discovery of a mechanism for this effect is 
imperative. 
In summary, the results presented in this chapter further clarify the mechanism 
of Irga6 and Irgb6 aggregate formation and clearance in the absence of Irgm1.  Our 
ultimate goal for this research remains to determine how the IRG protein system 
promotes cell autonomous immune responses to intracellular infection, and to expand 
this understanding to include how human IRGM functions in innate immunity.  
3.4 Materials and methods 
3.4.1 Cell culture 
Irgm1 (LRG-47)-deficient and Irgm3 (IGTP)-deficient mice were generated as 
described previously [215]. The mice were maintained according to Institutional Animal 
Care and Use Committee-approved protocols at the Durham VA and Duke University 
Medical Centers (Durham, NC). Mouse embryonic fibroblasts were derived from these 
mouse lines and immortalized by the standard 3T3 procedure [216].  Atg5-deficient 
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fibroblasts were a gift from Herbert Virgin, Washington University, St. Louis, MO. 3T3 
fibroblasts were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS 
(Hyclone, Logan, UT); 10 ug/mL ciprofloxacin was occasionally added to control 
infection. 18-24 hours prior to many experiments (as indicated in the text), 100 units/ml 
IFN-γ (#407320, Calbiochem, EMD Biosciences, San Diego, CA or #IF005, Millipore, 
Billerica, MA) and 100 nM bafilomycin A1 (#B1793, Sigma, St. Louis, MO), were added 
to the culture medium. 
Primary BMM were isolated from the tibia and femurs of 2- to 4-month-old mice. 
Bone marrow was flushed from the bones using a 27-gauge needle fitted to a syringe 
filled with DMEM, and the marrow was dispersed by drawing through the needle three 
to four times. Red cells were lysed with ACK lysing buffer (Invitrogen). Adherent cells 
were cultured for 6 days in bone marrow macrophage medium (culture medium 
supplemented with 30% (v/v) L929 cell-conditioned culture medium). The cells were 
cultured on Petri dishes, resulting in cultures that were loosely adherent and easily 
removed from the plates with cell dissociation buffer (#13150–016, Invitrogen). After day 
6, procedures diverged depending on the experiment. 
3.4.2 Transfection and nucleofection 
DNA transfections were performed using X-tremeGENE 9 or HP transfection 
reagent (#06365779001, Roche, Pleasanton, CA) according to manufacturer’s instructions.  
Nucleofections were performed using the Amaxa Biosystems Nucleofector II (Lonza, 
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Basel, Switzerland), along with nucleofector kit R (#VCA-1001, Lonza), according to 
manufacturer’s instructions.  MEF were nucleofected using program number U-30, and 
BMM were nucleofected using program number Y-1. 
3.4.3 Knock-downs 
siRNA transfections were performed using Lipofectamine RNAiMAX (#13778, 
Invitrogen) according to manufacturer’s instructions.  siRNAs were transfected 
overnight, and assays were performed either immediately or 24 hours later, as indicated 
in the text.  siRNAs utilized include Stealth® siRNA Sqstm1 #MSS207329 (#1320001, 
Invitrogen), Stealth® RNAi Negative Control High GC duplex (#12935-400, Invitrogen), 
Silencer® Select siRNA Irgm1 #s68045 (#4390771, Invitrogen), and Silencer® Select 
Negative Control No. 1 siRNA (#4390843, Invitrogen). 
3.4.4 Immunocytochemistry 
Cells were plated on poly-D-lysine-coated (#P7280, Sigma) coverslips and 
subjected to treatment conditions as described in the text.  Cells were then fixed with 4% 
paraformaldehyde (w/v) in PBS for 15 min, rinsed in 100 mM glycine/ PBS for 5 min, and 
permeabilized with 0.2% (w/v) saponin/PBS for 10 min. Cells were blocked with 10% 
(v/v) FCS/PBS for 60 min. As indicated in the text, the cells were then stained with 
various primary antibodies for 60 min, followed by AlexaFluor-conjugated secondary 
antibodies (Molecular Probes/Invitrogen) for 60 min. Primary antibodies used include 
anti-p62/Sqstm1 rabbit polyclonal antiserum (#ab91526, Abcam, Inc.) at 1:500, anti-Irga6 
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rabbit polyclonal antiserum 165/3 [51] at 1:4000, and anti-LC3B mouse monoclonal 
antibody (#M152–3, MBL International, Woburn, MA) at 1:50.  Images were collected on 
an Olympus IX70 microscope equipped with a Hamamatsu C8484–03G01 digital 
camera. Cells were magnified x1000.  Wide-field fluorescence images were collected 
using Metamorph 6.2.3.5. 
3.4.5 Western blotting 
Western blot analyses were performed according to standard protocols. In brief, 
lysates were boiled in SDS and separated on 8–16% gradient Tris-glycine gels (#EC60485, 
Invitrogen). Proteins were transferred overnight to Immobilon synthetic membranes 
(Millipore). Membranes were blocked in 5% (w/v) milk in TBS-Tween 20 for 60 min, then 
incubated in primary antibody for 60 min, washed, and incubated in secondary antibody 
for 60 min. Primary antibodies utilized include anti-p62/Sqstm1 rabbit polyclonal 
antiserum (#ab91526, Abcam, Inc.) at 1:500, anti-Irga6 rabbit polyclonal antiserum 165/3 
[51] at 1:2000, anti-actin clone C4 mouse monoclonal antibody (#MAB1501, Millipore) at 
1:1500, and anti-GFP rabbit polyclonal antiserum (#A6455, Invitrogen) at 1:500.  
Secondary antibodies used were goat anti-rabbit (H+L) HRP-conjugated IgG and goat 
anti-mouse (H+L) HRP-conjugated IgG (#AP307P and #AP308P, Millipore) at 1:1000.  
Blots were developed in SuperSignal west pico chemiluminescent substrate (#34708, 
Thermo Scientific, Rockford, IL) and imaged on a Kodak Image Station 4000R using 
Carestream Molecular Imaging software. 
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Carestream software was also used to quantify band intensities.  The “find lanes” 
feature was used, and lanes were adjusted manually as necessary.  The “find bands” 
feature was then used, and extraneous bands were deleted.  The band intensity was 
measured as the sum intensity of the resultant band peak. 
3.4.6 TUBE 1 pull-down of polyubiquitinated protein 
Wild-type, Irgm1-/-, and Irgm3-/- 3T3 cells were grown in 15-cm tissue culture 
dishes and exposed to 100 units/ml IFN-γ for 24 h prior to lysis. Cells were washed in 
PBS and lysed in 0.6 ml of lysis buffer (50mM Tris-HCL (pH 7.4), 0.15 M NaCl, 1mM 
EDTA, 1% Nonidet P-40, 10% glycerol). Input control samples were obtained by 
removing 0.2-ml aliquots and centrifuging at 16,000 x g at 4 °C for 5 min. Supernatants 
were mixed 3:1 with 4x sample buffer containing 0.4 M DTT (Invitrogen). To assay for 
detergent-insoluble protein aggregates that might sediment during centrifugation, 
pellets were suspended in 0.2 ml of 1x sample buffer containing 0.1 M DTT. Viscosity of 
the pellet suspension was reduced by 10–15 passages through a 23-gauge needle 
attached to a 1-ml syringe. To keep aggregated proteins in the suspension, the lysates 
were not cleared by centrifugation. Agarose beads coupled to tandem ubiquitin binding 
entity 1 (TUBE 1, LifeSensors, Malvern, PA) or uncoupled beads were equilibrated in 
TBS-T (10mM Tris-HCl (pH 8.0), 0.15 M NaCl, 0.05% Tween 20) according to the 
supplier’s recommendations.  A sedimented bead volume of 30 ul was used per pull-
down sample. Lysates were incubated with uncoupled agarose beads for 30 min at 4 °C. 
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Beads were sedimented at low speed (700 x g), and the supernates were transferred to 
tubes containing TUBE 1-coupled beads. Incubation at 4 °C was continued for 1 h. Beads 
were sedimented and washed in TBS-T a total of four times.  Beads destined for 
proteomic analysis were stored at 4ºC in 100 uL of storage buffer [PBS, 1:50 Protease 
Inhibitor Cocktail Set III (#539134, Calbiochem), 50 uM DUb inhibitor PR-619 (#SI9619, 
LifeSensors)] until further analysis. 
3.4.7 Proteomic analysis of TUBE-1 pull-down protein 
After TUBE-1 pull-down (see above), proteins were eluted from beads by boiling 
in NuPAGE MES SDS running buffer  (#NP002, Invitrogen) and separated on a 4–12% 
gradient Bis-Tris gel (#NP0321, Invitrogen).  Proteins were visualized via coomassie 
staining (#LC6025, Invitrogen); the control lane was divided into two gel slices and the 
sample lanes were divided into six slices each to minimize masking effects from high 
concentrations of protein.  In-gel tryptic digestion was performed on each gel slice via 
standard protocol as previously described [222].  Samples were then analysed via GeLC-
MS/MS utilizing a SYNAPT G2 ToF mass spectrometer (Waters, Milford, MA).  
Resulting spectra were identified using the NCBI mouse protein database.  Semi-
quantitative comparisons were made between samples via the spectral-counting 
method. 
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3.4.8 Tandem fluorescence studies 
Primary MEFs were cultured as described above, nucleofected with pDest-tfLC3 
as described above, then plated in 35mm poly-D-lysine coated glass-bottom culture 
dishes (#P35GC-1.0-14-C, MatTek, Ashland, MA).  Plates were incubated at 37ºC 
overnight, then rinsed with PBS to remove dead cells.  100 U/mL interferon-γ and, when 
appropriate, 100 nM bafilomycin A1, was added, and cells were incubated at 37ºC for 
18-24 h prior to imaging. 
BMM were cultured as described above; on day 6 of culture in BMM medium, 
cells were  nucleofected with pDest-tfLC3 as described above, replated in fresh petri 
dishes, and incubated at 37ºC overnight.  Cells expressing high levels of both mCherry 
and GFP fluorescence (approximately 1-5% of input) were then isolated via FACS 
analysis utilizing a Becton Dickinson DiVa cell sorter run at 30 psi.  Live cells were 
determined in conventional fashion by using the FSC and SSC light scatter histogram.  
GFP was excited with a 488 nm laser running at 100mW power.  The GFP emission was 
collected behind a 530/30 bandpass filter.  mCherry was excited with a dye laser at 600 
nm and 200mW of power.  The mCherry fluorescence was collected behind a 620/22 
bandpass filter.  Resultant cells were then plated in 35mm poly-D-lysine coated glass-
bottom culture dishes (#P35GC-1.0-14-C, MatTek) in a minimal amount of media.  2-4 
hours after plating, 2 mL of culture medium containing 100 U/mL interferon-γ and, 
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when appropriate, 100 nM bafilomycin A1, was added to each plate.  Plates were 
incubated at 37ºC for 18-24 h prior to imaging. 
Images were collected on an inverted Leica DMI6000CS confocal microscope run 
with Leica LAS AF v2.6 software, utilizing an Argon laser emitting at 488 nm, a 561 nm 
diode laser, and an 8000 Hz resonant scanner to enable rapid multi-channel scanning 
and limit photo-damage.  Resultant images were analysed further using Metamorph 
6.2.3.5 software.  Images were separated into two channels, one red and one green, then 
thresholded to remove background fluorescence.  Thresholded channels were then 
overlaid to generate one image.  Images were randomized and quantified in a treatment-
blinded fashion. 
3.4.9 Data Analysis 
Results are presented as mean ± SE unless otherwise indicated.  Treatment effects 
and/or variable interactions were determined by analysis of variance (ANOVA).  Where 
such effects were found, post-hoc analysis for specific mean comparisons was completed 
using Tukey’s HSD test.  Significance levels were set at p < 0.05 (95% confidence, two-
tailed) for all analyses. 
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4. The regulation of Irga6 and Irgb6 aggregate formation 
and clearance by guanylate-binding proteins 
4.1 Introduction 
In chapter 2 of this dissertation, we established that in the absence of Irgm1, the 
GKS IRG proteins Irga6 and Irgb6 form aggregates which colocalize with 
macroautophagic markers.  These aggregates further colocalize with Gbp2, a member of 
the guanylate-binding protein family which is closely related to the IRG family and is 
also involved in innate immune functions, as outlined further in chapter 1.  The 
colocalization of Gbp2 with GKS IRG protein aggregates implies a functional 
relationship between these two protein families which has been previously undescribed.  
We further demonstrated in chapter 2 that, while Irga6 was precipitated by a K63-linked 
ubiquitination binding construct, no detectable Gbp2 was similarly precipitated.  We 
clarified this finding in chapter 3, showing that Gbp2 was actually precipitated by this 
same construct at levels too insignificant to be picked up by western, but that unlike 
Irga6, levels of K63-linked ubiquitination did not change in the absence of Irgm1. 
These data imply that Gbp2 is not specifically targeted to macroautophagic 
degradation in the absence of Irgm1, unlike Irga6.  The small amount of Gbp2 picked up  
by the K63-linked ubiquitination binding construct may be precipitated because it 
associates with K63-linked ubiquitinated proteins, and not because it is itself tagged.  
Furthermore, the lack of change in the abundance of Gbp2 precipitated from wild-type 
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and Irgm1 deficient lysates suggests that Gbp2 is not regulated by GMS IRGs in the 
same fashion as is Irga6. 
From these findings, we have developed the following hypothesis:  Gbp2 
colocalizes with GKS IRG protein aggregates in the absence of Irgm1 because it is a part 
of the macroautophagic machinery utilized to degrade protein aggregates.  This 
hypothesis is further supported by previous data indicating roles for other guanylate-
binding proteins in the process of macroautophagy, including direct interactions 
between Gbp1 and p62 (outside of the ubiquitin-binding domain) and a decreased 
degradation rate of p62 in its absence, as well as direct interactions between Gbp7 and 
Atg4b, the LC3 protease, along with defects in autophagosomal closure in Gbp7-
deficient cells [85]. 
In this chapter, we will further explore this hypothesis.    We will demonstrate 
that Irga6 protein aggregates do not form in Gbp-deficient (but Irgm1 expressing) cells, 
indicating that Gbps are not involved in the prevention of Irga6 aggregate formation.  
We will further establish that, unlike Irga6, Gbp2 protein levels are unaffected by Irgm1 
deficiency, which implies that Gbp2 expression is not downregulated in the absence of 
Irgm1 and is therefore not toxic to the cell.  In addition, we will show the lack of a direct 
interaction between Gbp2 and Irgm3, suggesting that GMS IRGs do not directly regulate 
GBPs.  We will reveal that the number of Gbp2 puncta in Irgm1-deficient cells decreases 
when autophagy is upregulated by starvation, demonstrating a role for macroautophagy 
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in the clearance of these puncta.  We will show that Gbp2, but not Irga6, forms large 
punctate structures in the presence of protein aggregates in wild-type cells.  And finally, 
we will demonstrate that a greater number of Irga6 aggregates are found in Gbp- and 
Irgm1- doubly deficient MEFs than in Irgm1-deficient MEFs, indicating a role for 
guanylate binding proteins in the clearance of Irga6 aggregate inclusions.  Taken 
together, these data indicate a role for chromosome 3 guanylate-binding proteins in the 
macroautophagic clearance of protein aggregates, including those formed by GKS IRGs 
in the absence of GMS IRG proteins. 
4.2 Results 
4.2.1 Absence of chromosome 3 Gbp locus does not lead to the 
presence of Irga6 aggregates 
In order to address whether guanylate-binding proteins are part of the protein 
aggregate clearance machinery, we first must address competing hypotheses describing 
roles for guanylate-binding proteins.  A previous study into the relationship between 
GBPs and IRGs demonstrated that the five GBP genes and one GBP pseudogene found 
on murine chromosome 3 were necessary to the proper localization of Irgb6 to the 
Toxoplasma gondii-containing vacuole; the authors thus proposed that guanylate-binding 
proteins actively regulate the localization of GKS IRGs [95].  Thus, we asked whether  
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Figure 17:  Loss of chromosome 3 Gbp proteins does not cause Irga6 
aggregation.  A) Sample Images.  MEFs of the indicated genotypes were incubated with 
100 U/mL IFN-γ for 24h, then processed for immunofluorescence.  B)  The percentage of 
cells containing Irga6 aggregates was quantified in a treatment-blinded fashion.  Data 
represent n=5 trials with 10 cells quantified per treatment per trial.  Differences in 
populations are not statistically significant by Student’s T-test. 
 
GBP proteins might also prevent the premature activation and aggregation of GKS IRGs 
such as Irga6. 
To determine this, we utilized the MEFs from the previous study in which a 173 
kb portion of murine chromosome 3 containing a large GBP gene locus has been deleted 
[95].  The specific GBPs deleted include Gbp1-3, Gbp5, Gbp7, and Gbp2ps; we will use 
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the notation Gbp(chr 3)KO to denote this genotype for the rest of this dissertation.  We 
compared the localization of Irga6 in WT and Gbp(chr 3)KO primary MEFs, and found no 
statistically significant differences in the average number of aggregates per cell; in each 
cell type, Irga6 largely maintained its normal localization, appearing to be concentrated 
in the endoplasmic reticulum (Figure 17, A).  Approximately 20% of cells of each 
genotype displayed one or more large Irga6 puncta (Figure 17, B), consistent with our 
results in chapter 2 of this dissertation; no statistical difference was found in the 
percentage of cells containing Irga6 aggregates between the two populations.  This result 
indicates that none of the GBP genes found on murine chromosome 3, including Gbp2, 
functions to downregulate the formation of GKS IRG protein aggregates, and thus these 
guanylate-binding proteins maintain a different functional relationship with GKS IRGs 
than do the GMS IRGs. 
4.2.2  Levels of Gbp2 protein are unaffected by Irgm1 deficiency 
A second alternative hypothesis to the idea that GBPs regulate macroautophagic 
clearance of protein aggregates is that GBPs  are regulated by GMS IRGs, and similarly 
to GKS IRGs, aggregate in their absence.  Our previous data indicating that Irga6 is 
targeted to specific macroautophagy via K63-linked ubiquitin, while Gbp2 is not, argues 
against this hypothesis.  However, this is only one line of evidence, and there are other 
aspects of the GMS-GKS IRG relationship which we can explore to ascertain if GMS 
IRGs regulate GBPs.  For example, we and others have established that in the absence of 
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Irgm1, protein levels of the GKS IRGs Irga6 and Irgb6 decrease [60].  We initially 
proposed that this decrease is due to a negative feedback loop which downregulates 
expression of the toxically aggregated GKS IRGs to prevent further detrimental effects 
on cellular function.  Given our results presented in chapter 3, however, showing that 
Irgm1 has little effect on macroautophagy, we here propose a different theory, that  
 
 
Figure 18:  Irgm1 deficiency does not lead to a decrease in Gbp2 protein levels.  
3T3 MEFs of the indicated genotypes were treated with 100 U/mL IFNγ for 24h, then 
were processed for western analysis.  Raw band intensities were adjusted for actin levels 
and normalized to wild-type levels.   No statistical difference in the populations was 
detected by Student’s T-test.  Data represent n=3 trials, with 1-3 replicates per trial. 
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overall levels of these GKS IRG proteins decrease because they are being degraded 
through macroautophagy.  Thus, if Gbp2 aggregates in a similar fashion to GKS IRGs in 
the absence of Irgm1, its protein levels should similarly decrease.  We decided to 
ascertain whether Irgm1 deficiency has a similar effect on Gbp2 protein levels to provide 
further evidence that GMS IRGs do not directly regulate GKS IRGs.  We measured p62 
protein levels (normalized to actin) via western analysis in wild-type and Irgm1-
deficient cells; as expected, we found that Irgm1 deficiency had no statistically 
significant effect on Gbp2 protein levels (Figure 18).  These data demonstrate that Gbp2 
expression does not fluctuate in the absence of Irgm1, thus suggesting that large Gbp2 
puncta seen in the absence of Irgm1 are not aggregates to be degraded.  Furthermore, 
this suggests that Gbp2 is not regulated by GMS IRGs. 
4.2.3  Gbp2 does not directly interact with Irgm3 
Another facet of the GMS-GKS IRG relationship is direct interactions between 
these two subfamilies.  A previous study demonstrated several of these direct 
interactions, including between Irgm1-Irgm3, Irgm1-Irga6, Irgm3-Irga6, and Irga6-Irgb6, 
via yeast two-hybrid assays and/or GST pulldowns [62].  Importantly, our lab has spent 
a significant amount of time attempting to confirm these direct interactions via co-
immunoprecipitation assays, GST-pulldowns, and/or FRET assays.  We have been 
unable to provide clear evidence of interactions between Irgm1-Irgm3, Irga6-Irgb6, or 
Irgm1-Irgb6 (data not shown).  We were able to demonstrate, however, that Irgm3 is  
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Figure 19:  Gbp2 does not directly interact with Irgm3.  Wild-type 3T3 MEFs 
were incubated with 100 U/mL IFN-γ for 24h, then were or were not loaded with 0.5 
mM of the indicated guanine nucleotides, as indicated.  Lysates were then used for 
immunoprecipitation with anti-Irgm3 antibodies.  Resultant proteins were subjected to 
western analysis.  Data are representative of three trials.  This experiment was done by 
Stanley Henry. 
 
able to precipitate Irgb6 in a nucleotide-independent manner (Figure 20).  We thus 
decided to determine whether Gbp2 also interacts with Irgm3, as evidence of a direct 
regulatory effect of this GMS IRG on guanylate binding proteins.  We were unable to co-
precipitate Gbp2 using an Irgm3 antibody, from which we infer that Gbp2 and Irgm3 do 
not directly interact (Figure 19).  This result is further evidence that GMS IRGs do not 
regulate the guanylate-binding proteins. 
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4.2.4  Gbp2 is affected by macroautophagic processes 
Based on the evidence we have now shown, it seems that GBPs do not regulate 
GKS IRGs, and GMS IRGs do not regulate GBPs.  Thus we turn our attention to our 
original hypothesis: that Gbp2 colocalizes with GKS IRG protein aggregates in the 
absence of Irgm1 because it is a part of the macroautophagic machinery utilized to  
 
 
Figure 20:  Induction of autophagy by starvation leads to fewer Gbp2 puncta in 
the absence of Irgm1.  MEFs of the indicated genotypes were incubated with 100 U/mL 
IFN-γ for 24h, and concurrently were or were not starved in Hank’s balanced salt 
solution for the final 4h.  Cells were then processed for immunofluorescence with αGbp2 
antibodies.  Data represent n = 2 trials, with 20-21 cells quantified per treatment per trial. 
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degrade protein aggregates. 
To study this hypothesis, we first wanted to establish a clearer link between 
Gbp2 and the process of macroautophagy; thus, we examined whether the number of 
Gbp2 puncta was affected by upregulation of autophagy.  We compared the number of 
Gbp2 puncta found in Irgm1-deficient MEFs to the number found in the same cells in 
which autophagic flux was additionally induced via starvation in Hank’s balanced salt 
solution (Figure 20).  The starved cells displayed fewer Gbp2 puncta per cell than the 
unstarved cells, indicating that upregulating macroautophagy leads to clearance of these 
puncta.  Given our previous findings that Gbp2 is not targeted to specific autophagy and 
that its expression level is unaffected by Irgm1 deficiency, these data further suggest that 
Gbp2 puncta are not aggregates, but are instead autophagosomal compartments.  
4.2.5 Gbp2, but not Irga6, localizes to protein aggregates 
If Gbp2 is a part of the general autophagic protein aggregate clearance 
machinery, as we have hypothesized, it should additionally colocalize with protein 
aggregates other than those formed by Irgm1 deficiency; that is, Gbp2 should colocalize 
with protein aggregates in wild-type cells.  We induced protein aggregation in wild-type 
cells utilizing both MG132 treatment (which blocks proteasomal function, leading to an 
accumulation of proteins unable to be degraded except through macroautophagy 
[107,223]), and puromycin treatment (which serves as a tRNA imitator, leading to the 
accumulation of prematurely terminated peptides called defective ribosomal products 
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or DRiPs, which form aggregate inclusions in the cell [224-226]).  The percentage of wild-
type cells displaying large Gbp2 puncta increased dramatically upon treatment with 
either of these two compounds; however, an equivalent increase in Irga6 puncta was not 
observed (Figure 21).  These findings can be interpreted in one of two ways.  First, it is  
 
 
Figure 21:  Gbp2, but not Irga6, displays a punctate localization in the presence 
of protein aggregates.  WT 3T3 MEFs of the indicated genotypes were incubated with 
100 U/mL IFN-γ for 24h, and concurrently were or were not treated with 5 ug/mL 
puromycin or 10 uM MG132 for the final 6h, as indicated.  Cells were then processed for 
immunofluorescence with αGbp2 or αIrga6 antibodies.  2x3 ANOVA indicates a 
significant interaction term, p < 0.05.  * p < 0.05 via Fisher’s PLSD test.  Data represent n = 
3 trials, with 20 cells quantified per treatment per trial. 
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possible that Gbp2 is for some reason sensitive to aggregation in response to these two 
treatments, while Irga6 is not.  A second interpretation, however, is that Gbp2 forms 
puncta in the presence of generic protein aggregates, rather than due to Irgm1 
deficiency, which would suggest once more that Gbp2 puncta are not themselves 
aggregates, but rather autophagosomes. 
4.2.6 Absence of chromosome 3 Gbp locus leads to an increase in 
the number of Irga6 aggregates 
Now that we have shown that Gbp2 forms puncta in the presence of protein 
aggregates which colocalize with autophagosomal markers, we next asked whether 
guanylate-binding proteins are involved in the clearance of protein aggregates, and 
more specifically, the Irga6 aggregates formed in the absence of Irgm1.  We stimulated 
Irga6 aggregate formation in wild-type and Gbp(chr 3)KO MEFs by treatment with Irgm1 
siRNA and compared the average number of Irga6 puncta found in these two 
genotypes.  On average, there were three times as many Irga6 puncta in cells lacking the 
GBP locus than in wild-type cells (Figure 22, A + C).  However, while every trial 
demonstrated an increase in aggregate number in GBP-deficient cells, the absolute 
number of aggregates per cell varied significantly by trial, likely due to variations in 
Irgm1 knockdown levels, which lead to no statistical difference between the two 
populations detected by Student’s T-test (Figure 22, B).  In order to compensate for the 
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effects of each trial on aggregate number, we took the log-transformed aggregate 
number ratios of Gbp(chr 3)KO to WT and compared them to the null hypothesis of no  
 
 
Figure 22:  Loss of chromosome 3 Gbp proteins leads to an increased number 
of Irga6 aggregates in Irgm1-deficient cells.  A)  Sample images.  Primary MEFs of the 
indicated genotypes were transfected with Irgm1 siRNAs overnight, then were treated 
with 100 U/mL IFNγ for 24h.  Cells were then processed for immunofluorescence.  B) 
Data table.  The number of large Irga6 puncta per cell was calculated in a treatment-
blinded fashion.  n=4 trials, with 4-10 cells per treatment per trial, were quantified.  C) 
Data from part B presented as the average ratio of the number of Irga6 aggregates in 
Gbp(chr 3)KO cells to the number of Irga6 aggregates in WT cells.  The observed log-
transformed ratios were compared to the null hypothesis of no differences in the 
number of Irga6 aggregates between genotypes (Irga6GbpKO / Irga6WT = 1) via one-group 
T-test; genotype was found to have a significant effect on the number of Irga6 
aggregates, p < 0.02. 
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difference in the number of Irga6 aggregates between genotypes (Irga6GbpKO / Irga6WT = 1) 
via one-group T-test.  This test indicated a significant effect of genotype on the number 
of Irga6 aggregates.  We therefore conclude that the chromosome 3 GBP locus is 
involved in the clearance of Irga6 aggregates.  It should be noted, however, that we did 
not examine the effects of the absence of the chromosome 3 GBP locus on overall levels 
of Irgm1.  We know of no evidence to suggest that this locus would affect Irgm1 
expression, but we cannot rule out the possibility.  It is therefore possible, although 
unlikely, that the increase in Irga6 aggregates in Gbpchr 3KO cells is due to a decrease of 
Irgm1 protein in these cells, and this contingency should be investigated. 
4.3 Discussion 
In this chapter, we have discussed the role of the guanylate-binding proteins in 
the formation and clearance of GKS IRG aggregates formed in the absence of GMS IRGs.  
In response to the hypothesis presented by others that GBPs are able to control the 
localization of IRGs, we presented evidence that GBPs do not regulate GKS IRG 
aggregate formation by demonstrating that loss of the guanylate-binding protein locus 
on the murine chromosome 3 does not lead to the formation of GKS IRG aggregates.  We 
showed that Gbp2 expression levels are unaffected by Irgm1 deficiency, implying that 
Gbp2 does not form aggregates in GMS IRG-deficient cells and thus is not regulated by 
GMS IRGs.  This conclusion was further supported by our inability to demonstrate 
direct interactions between GMS IRGs and GBPs.  We demonstrated that the number of 
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Gbp2 puncta found in Irgm1-deficient cells decreased when autophagy was upregulated 
by starvation, linking the fate of these structures to macroautophagy.  We revealed that 
Gbp2 puncta formation is linked not to GMS IRG deficiency, but to the presence of 
protein aggregates, and demonstrated that the chromosome 3 GBP locus is involved in 
clearance of the Irga6 aggregates formed in the absence of GMS IRGs. 
Together, these data support the hypothesis we proposed in chapter 2 of this 
dissertation: that Gbp2 colocalizes with GMS-IRG-deficiency-induced Irga6 aggregates 
not because it is aggregating, but because it is part of the autophagic machinery used to 
degrade protein aggregates.  This hypothesis is further supported by a previous study 
indicating a role for guanylate-binding proteins in macroautophagic processes [85].    
This study did not find that Gbp2 was necessary for cell-autonomous immunity to 
Listeria monocytogenes or Mycobacterium bovis, which is consistent with our supposition 
that Gbp2 is involved in aggregate clearance, a function not normally required for 
bacterial or protozoan resistance.  We speculate that Gbp2 may have evolved as an 
antiviral effector to combat toxic defective ribosomal products caused by viral 
interference with host translation.  However, it should be noted that a recent study 
found that Gbp2 localizes to the Toxoplasma gondii—containing vacuole and is necessary 
for control of T. gondii replication, implying that Gbp2 has roles in bacterial resistance 
outside of aggregate clearance [227].  The exact roles of Gbp2 in cell-autonomous innate 
immunity thus remain to be fully elucidated. 
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While the data presented here collectively support our hypothesis that Gbp2 is 
involved in the autophagy of protein aggregates, there is additional work that could be 
done which would significantly strengthen the conclusions we have drawn.  We 
suggested by the results of our co-immunoprecipitation that guanylate-binding proteins 
do not directly interact with immunity-related GTPases; however, this inference should 
be supported by more comprehensive yeast two-hybrid or pulldown studies exploring 
interactions between a larger set of GMS IRGs and guanylate-binding proteins.  Second, 
while we demonstrated that Gbp2 forms puncta in the presence of protein aggregates, a 
quantification of the colocalization between Gbp2 and ubiquitinated aggregates in these 
cells would significantly strengthen our position that Gbp2 is associated with generic 
protein aggregation.  Additionally, it would be instructive to separate Irgm1-deficient 
cell lysates on a native gel and examine whether Gbp2 and/or Irga6 multimeric 
complexes are found; we would predict that abundant Irga6 complexes would be found, 
but no Gbp2 complexes.  And finally, while we demonstrated that the chromosome 3 
GBP locus is involved in clearance of Irga6 aggregates, we did not discover which 
specific GBPs on this locus are responsible for this clearance.  Targeted knockdowns of 
specific GBPs and/or reconstitution of specific GBPs into the Gbp(chr 3)KO MEFs would 
elucidate the individual IRGs which contribute to aggregate degradation. 
In summary, the results presented in this chapter further clarify the mechanism 
of action of guanylate-binding proteins with respect to immunity-related GTPases.  
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These results further support previous research indicating a role for GBPs in 
macroautophagy, and provide impetus for studies into how the participation of 
guanylate-binding proteins in macroautophagy aids in cell-autonomous innate 
immunity to intracellular pathogens. 
4.4 Materials and methods 
4.4.1 Cell culture 
Irgm1 (LRG-47)-deficient and Irgm3 (IGTP)-deficient mice were generated as 
described previously [215]. The mice were maintained according to Institutional Animal 
Care and Use Committee-approved protocols at the Durham VA and Duke University 
Medical Centers (Durham, NC). Mouse embryonic fibroblasts were derived from these 
mouse lines and immortalized by the standard 3T3 procedure [216].  Atg5-deficient 
fibroblasts were a gift from Herbert Virgin, Washington University, St. Louis, MO. 3T3 
fibroblasts were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS 
(Hyclone, Logan, UT); 10 ug/mL ciprofloxacin was occasionally added to control 
infection. 18-24 hours prior to many experiments (as indicated in the text), 100 units/ml 
IFN-γ (#407320, Calbiochem, EMD Biosciences, San Diego, CA or #IF005, Millipore, 
Billerica, MA) and 100 nM bafilomycin A1 (#B1793, Sigma, St. Louis, MO), were added 
to the culture medium. 
Primary BMM were isolated from the tibia and femurs of 2- to 4-month-old mice. 
Bone marrow was flushed from the bones using a 27-gauge needle fitted to a syringe 
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filled with DMEM, and the marrow was dispersed by drawing through the needle three 
to four times. Red cells were lysed with ACK lysing buffer (Invitrogen). Adherent cells 
were cultured for 6 days in bone marrow macrophage medium (culture medium 
supplemented with 30% (v/v) L929 cell-conditioned culture medium). The cells were 
cultured on Petri dishes, resulting in cultures that were loosely adherent and easily 
removed from the plates with cell dissociation buffer (#13150–016, Invitrogen). After day 
6, procedures diverged depending on the experiment. 
4.4.2 Transfection and nucleofection 
DNA transfections were performed using X-tremeGENE 9 or HP transfection 
reagent (#06365779001, Roche, Pleasanton, CA) according to manufacturer’s instructions.  
Nucleofections were performed using the Amaxa Biosystems Nucleofector II (Lonza, 
Basel, Switzerland), along with nucleofector kit R (#VCA-1001, Lonza), according to 
manufacturer’s instructions.  MEF were nucleofected using program number U-30, and 
BMM were nucleofected using program number Y-1. 
4.4.3 Knock-downs 
siRNA transfections were performed using Lipofectamine RNAiMAX (#13778, 
Invitrogen) according to manufacturer’s instructions.  siRNAs were transfected 
overnight, and assays were performed either immediately or 24 hours later, as indicated 
in the text.  siRNAs utilized include Stealth® siRNA Sqstm1 #MSS207329 (#1320001, 
Invitrogen), Stealth® RNAi Negative Control High GC duplex (#12935-400, Invitrogen), 
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Silencer® Select siRNA Irgm1 #s68045 (#4390771, Invitrogen), and Silencer® Select 
Negative Control No. 1 siRNA (#4390843, Invitrogen). 
4.4.4 Immunocytochemistry 
Cells were plated on poly-D-lysine-coated (#P7280, Sigma) coverslips and 
subjected to treatment conditions as described in the text.  Cells were then fixed with 4% 
paraformaldehyde (w/v) in PBS for 15 min, rinsed in 100 mM glycine/ PBS for 5 min, and 
permeabilized with 0.2% (w/v) saponin/PBS for 10 min. Cells were blocked with 10% 
(v/v) FCS/PBS for 60 min. As indicated in the text, the cells were then stained with 
various primary antibodies for 60 min, followed by AlexaFluor-conjugated secondary 
antibodies (Molecular Probes/Invitrogen) for 60 min.  Primary antibodies used include 
anti-Irga6 rabbit polyclonal antiserum 165/3 [51] at 1:4000 and anti-Gbp2 rabbit 
polyclonal antiserum (Jörn Coers, Duke University) at 1:500.  Images were collected on 
an Olympus IX70 microscope equipped with a Hamamatsu C8484–03G01 digital 
camera. Cells were magnified x1000. Wide-field fluorescence images and z-stacks were 
collected using Metamorph 6.2.3.5. 
4.4.5 Western blotting 
Western blot analyses were performed according to standard protocols. In brief, 
lysates were boiled in SDS and separated on 8–16% gradient Tris-glycine gels (#EC60485, 
Invitrogen). Proteins were transferred overnight to Immobilon synthetic membranes 
(Millipore). Membranes were blocked in 5% (w/v) milk in TBS-Tween 20 for 60 min, then 
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incubated in primary antibody for 60 min, washed, and incubated in secondary antibody 
for 60 min. Primary antibodies utilized include anti-Irgb6 rabbit polyclonal antiserum 
[60] at 1:1000, anti-Gbp2 rabbit polyclonal antiserum (Jörn Coers, Duke University) at 
1:500, and anti-actin clone C4 mouse monoclonal antibody (#MAB1501, Millipore) at 
1:1500.  Secondary antibodies used were goat anti-rabbit (H+L) HRP-conjugated IgG and 
goat anti-mouse (H+L) HRP-conjugated IgG (#AP307P and #AP308P, Millipore) at 
1:1000.  Blots were developed in SuperSignal west pico chemiluminescent substrate 
(#34708, Thermo Scientific, Rockford, IL) and imaged on a Kodak Image Station 4000R 
using Carestream Molecular Imaging software. 
Carestream software was also used to quantify band intensities.  The “find lanes” 
feature was used, and lanes were adjusted manually as necessary.  The “find bands” 
feature was then used, and extraneous bands were deleted.  The band intensity was 
measured as the sum intensity of the resultant band peak. 
4.4.6 Immunoprecipitation 
For the immunoprecipitation assay reported in Figure 20, 50 ul of protein A-
coupled paramagnetic beads (Dynabeads, Invitrogen) were isolated on a magnetic stand 
(Promega, Madison, WI) and suspended in 0.2 ml of PBS containing 0.02% (v/v) Tween 
20 (PBS-T). One microliter of either preimmune serum or anti-Irgm3 polyclonal 
antiserum [228] was added, and bead suspensions were incubated with rotation at room 
temperature for 20 min. Antibody-bound beads were washed once in PBS-T prior to 
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addition of cell lysates. Wild-type, Irgm1-/-, or Irgm3-/- 3T3 cells in 10-cm tissue culture 
dishes were given 100 units/ml IFN-γ for 24 h and lysed in PBS containing 1% (v/v) 
Nonidet P-40 and proteinase inhibitors (Calbiochem). 0.35 ml cell lysate with or without 
0.5 mM GDP or GTPγS was added to the antibody-bound beads and incubated at room 
temperature for 20 min with rotation. Beads were magnetically separated and washed 
three times. Washed beads were removed to a fresh tube and suspended in 1x sample 
buffer (0.09 M DTT, 1.2% SDS, 0.012 M EDTA, 0.0025% bromphenol blue, 6% sucrose). 
Samples were heated to 100 °C to elute proteins and used for western blotting. To 
minimize cross-reaction of the secondary antibody with eluted IgG, a secondary 
antibody that does not recognize denatured IgG (Clean Blot, Thermo Scientific) was 
used. 
4.4.7 Data Analysis 
Results are presented as mean ± SE unless otherwise indicated.  Treatment effects 
and/or variable interactions were determined by analysis of variance (ANOVA), 
Student’s T-test, or one-group T-test, where appropriate.  Where such effects were found 
via ANOVA, post-hoc analysis for specific mean comparisons was completed using 
Fisher’s PLSD.  Significance levels were set at p < 0.05 (95% confidence, two-tailed) for 
all analyses. 
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5. Conclusions 
The immunity-related GTPases, or IRGs, are a family of interferon-induced, 
dynamin-like proteins with roles in cell-autonomous innate immunity.  The family can 
be divided into two subcategories:  the GKS IRGs, which comprise the majority of the 
family and contain the canonical P-loop GTP-binding motif (GxxxxGKS), and the GMS 
IRGs, which contain a methionine substitution (GxxxxGMS) in this motif [38].  The 
differences in GTP-binding caused by this alteration likely impart distinct functions to 
these two classes of IRGs.  While members of the larger GKS IRG subfamily are thought 
to utilize their putative dynamin-like membrane modulation ability to effect membrane 
stripping from pathogen-containing compartments [229],  the roles of the GMS IRG 
subfamily in innate immunity remain poorly characterized. 
Previous studies reported in the literature have developed a working model of 
IRG function which describes a role for GMS IRGs in preventing the premature 
activation of GKS IRGs.  In this model, the GMS IRGs, which are localized to the Golgi 
apparatus, the endoplasmic reticulum, and other intracellular membrane compartments, 
directly interact with GKS IRGs and prevent their activation at those membranes [62].  
Upon direct infection of the cell by an invasive pathogen, the GKS IRGs are trafficked to 
the pathogen-containing compartment, which lacks robust GMS IRG association [73], 
where they effect membrane stripping and exposure of the invading organism to the 
cytoplasmic environment [229].  In the event of premature activation of GKS IRGs, 
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perhaps due to the disabling of GMS IRG function or a mismatch in levels of these two 
protein subfamilies, GKS IRGs are incorrectly trafficked to compartments which 
resemble aggregate inclusions, where they must be degraded to prevent toxic effects on 
cellular functions [60]. 
While this model incorporates much of the current literature surrounding IRG 
function, it does not account for several experimental results.  For example, it has been 
demonstrated that more profound deficiencies in innate immunity exist in mice lacking 
GMS IRGs than in mice lacking GKS IRGs, which is unexpected if GMS and GKS IRGs 
function in the same innate immune pathway [55,61,63].    This finding could be 
explained by redundancies in the functions of the extensive group of mouse GKS IRGs 
that could compensate for loss of one member, or alternatively by pathological 
consequences of GKS IRG aggregate formation occurring in the absence of GMS IRGs.  
However, certain species, including primates, encode only GMS IRGs within their 
genomes [38,39], suggesting an additional explanation: that GMS IRGs encompass a 
broader range of activities than mere control of GKS IRG function. 
The goals of the research undertaken for this dissertation were to extend this 
working model of IRG function to include a role or roles for GMS IRGs outside of GKS 
IRG control.  We initially proposed that GMS IRGs might exhibit regulatory control over 
a related family of interferon-induced GTPases, the guanylate-binding proteins, by 
demonstrating the mislocalization of Gbp2 in the absence of GMS IRGs to the same 
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structures as the similarly mislocalized GKS IRGs.  This finding suggests that GMS IRGs 
may control Gbp2 in a similar manner to their control of GKS IRGs.  This discovery of a 
broader utility for GMS IRGs would help explain the discrepancy in innate immune 
responses between GMS- and GKS- lacking mice, since GMS-IRG lacking mice would be 
deficient for both the GKS IRG and Gbp2 response pathways; additionally, since 
primates encode a variety of guanylate-binding proteins, this finding could also explain 
why certain species do not encode GKS IRGs.  However, in subsequent studies, we 
found evidence that GMS IRGs may not exert a direct control over Gbp2 localization; 
rather, it is likely that Gbp2 localizes to GKS IRG aggregates  because it is directly 
involved in their macroautophagic clearance.  Thus, the localization of Gbp2 in the 
absence of GMS IRGs, while providing tantalizing hints to the poorly understood 
function of guanylate-binding proteins in innate immunity, does not provide evidence 
of a role for GMS IRGs outside of GKS IRG regulation. 
A second possible broader regulatory role of GMS IRGs that could explain their 
increased importance to innate immunity is a previously proposed role in controlling 
macroautophagy.  While this is supported by previous studies indicating that 
overexpression of GFP-tagged Irgm1 in macrophage-like cells induced autophagosome 
formation [41,191], other studies do not support this role, including those showing that 
GFP-tagged Irgm1 may be constitutively activated [56], and that interferon-gamma-
induced autophagy does not require Irgm1 [202].  We proposed that Irgm1 might play a 
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role in autophagosome maturation, as its absence led to a buildup of LC3-positive but 
LAMP-1-negative compartments; thus, we examined whether faulty autophagic flux in 
the absence of Irgm1 might be responsible for the observed GKS IRG aggregates.  
However, we were unable to detect an effect of the absence of Irgm1 on the maturation 
of autophagosomes in MEFs, and only a very small and statistically insignificant 
decrease in bone-marrow macrophages.  Additionally, given the cell-specific differences 
in assay results we found, we attempted to confirm that Irgm1 expression in fibroblasts 
induces autophagosome initiation, but found no difference in LC3-tagged compartment 
formation in these cells.  Our results thus do not suggest a role for Irgm1 in the 
modulation of macroautophagy.  Nevertheless, it remains surprising that  GMS IRGs do 
not play a direct role in modulating autophagy, as Crohn’s disease related intestinal 
pathologies of human patients with SNPs in the core autophagy gene Atg16L1 closely 
resemble those of patients with SNPs in the IRGM locus, implying that these two genes 
function in the same autophagic pathway [199,200].  Future studies are needed to 
investigate a role for human IRGM in macroautophagy modulation. 
As we have found no evidence that GMS IRGs either directly regulate the 
guanylate-binding proteins, nor that they directly affect macroautophagy, the initial goal 
of our research study, which aimed to uncover the role(s) of GMS IRGs in innate 
immunity outside of the regulation of GKS IRGs, remains largely unfulfilled.  However, 
the results of our studies do contribute to the working model of overall IRG function in 
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other ways.  For example, although GKS IRGs are known to localize to pathogen-
containing compartments, the mechanisms whereby IRG proteins recognize and are 
trafficked to these vesicles are currently a mystery.  We have presented here the 
intriguing finding that the GKS IRGs Irga6 and Irgb6 are polyubiquitinated (possibly 
through K63 linkages) in wild-type cells, and that this ubiquitination increases in the 
case of GMS IRG deficiency.  We additionally demonstrated that these ubiquitinated 
proteins colocalize with macroautophagic markers, implying that the ubiquitination tag 
targets these GKS IRGs to the macroautophagic system.  One interpretation of these 
findings is that macroautophagy is utilized to degrade large aggregate inclusions, which 
GKS IRGs are predisposed to form.  However, we also propose an alternative 
interpretation: that ubiquitination of GKS IRGs mediates their trafficking to pathogen-
containing compartments, a process that utilizes the  macroautophagic machinery of the 
cell.  In this scenario, the ubiquitinated GKS IRGs would not be present as aggregates 
inside degradative autophagic vacuoles, but rather would be present on the surface of 
the autophagic vacuole where they would presumably enact their function. This 
hypothesis is supported by a previous study that indicates that Irga6 fails to localize to 
the pathogen-containing vacuole in the presence of GMS IRGs but the absence of a 
functional autophagic system [221].  Additionally, a second study indicates that Irgb6 
fails to localize to pathogen-containing vacuoles in the absence of the chromosome 3 
guanylate-binding protein locus [95], which, when combined with previous data 
 131 
indicating that GBPs play a role in specific macroautophagy, suggests that GBP-
mediated autophagic trafficking is responsible for the correct targeting of Irgb6 to the 
pathogen-containing vacuole. 
An additional benefit of the research presented in this dissertation is that we 
were able to contribute to understanding the mechanism of action of the guanylate-
binding proteins, an interferon-induced GTPase family which has been less well-
studied.  Our data suggest that Gbp2 plays a role in the specific autophagic clearance of 
protein aggregates, as we demonstrated both that Gbp2 punctate structures form in the 
presence of generic protein aggregates, and that the murine chromosome 3 GBP locus is 
involved in the degradation of Irga6 protein aggregates.  These data add to a previous 
study indicating a role for certain chromosome 3 GBPs in macroautophagic processes 
[85].  Further, these findings raise the interesting question of how macroautophagy of 
cellular aggregates could contribute to innate immunity.  One possibility is that Gbp2 is 
involved in the targeting of substrates marked with a particular signal, such as K63-
linked ubiquitination, to autophagosomes.  Considering that many pathogen-containing 
compartments accumulate autophagosomal markers, this Gbp2-mediated targeting 
could be used to traffic anti-microbial effectors, including GKS IRGs, to phagosomes.  
Additionally, certain pathogens may employ survival strategies within the cell that 
promote the formation of defective protein products, such as viral interference with host 
translation; Gbp2 may function to lessen toxic effects on cells as a result of such 
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pathogenic effectors.  Further research is necessary to fully elucidate the role of Gbp2 in 
cell-autonomous defense against intracellular pathogens. 
In summary, we have presented research in this dissertation which increases our 
overall understanding of the functions of the immunity-related GTPases in innate 
immunity.  While we were not able to establish a role for GMS IRGs outside of control of 
GKS IRGs, we were able to relate the GKS IRGs Irga6 and Irgb6 to the macroautophagic 
system, a finding which suggests a trafficking mechanism to the pathogen-containing 
compartment for these proteins.  Additionally, we demonstrated that Gbp2 is involved 
in the macroautophagic clearance of protein aggregates, which has important 
implications for the understanding of the functions of the guanylate-binding proteins.  
Together, these findings contribute to our overall scientific understanding of interferon-
induced innate immunity. 
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Appendix A:  Proteins Identified in TUBE1 Pull-down 
Proteomic Screen 
 
Immunity Related Proteins 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Gbp2 NP_034390.1 3 1.2 
Gbp6 NP_919317.2 3 -1.5 
Gvin1 / Vlig1 NP_001229969.1 1 1.1 
IFITM3 NP_079654.1 1 -2.1 
Irga6 NP_068564.4 4 3.6 
Irgb6 NP_001138636.1 2 1.5 
MIF NP_034928.1 1 -2.0 
Peroxiredoxin-1 NP_035164.1 2 -1.1 
Stat1 
(isoform 2) 
NP_001192243.1 1 -2.8 
TOLLIP NP_076253.1 1 -1.1 
 
 
Protein Degradation 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
p62 NP_035148.1 3 -1.1 
PLAA / PLAP NP_766283.2 2 1.0 
Polyubiquitin-C NP_062613.3 14 -1.1 
Trypsin 10 
(Precursor) 
NP_001034085.1 1 1.9 
Serine Protease 1 
(precursor) 
NP_444473.1 1 -1.0 
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SUMO3 
(precursor) 
NP_064313.1 2 -1.2 
Trypsinogen 7 
(precursor) 
NP_075822.3 1 1.1 
Ubiquilin-1 
(isoform 1) 
NP_081118.4 4 1.2 
UBR2 
(isoform 1) 
NP_666190.2 1 -2.1 
 
 
Proteasome Catalytic Subunits 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
α1 NP_036095.1 1 -1.5 
α3 NP_035314.3 2 -1.5 
α4 NP_036096.1 2 1.0 
α6 NP_036098.1 1 -2.0 
α7 NP_036099.1 3 1.2 
β3 NP_036101.1 2 1.3 
β6 
(precursor) 
NP_032972.3 1 -1.3 
β10 
(precursor) 
NP_038668.2 1 -1.7 
 
Proteasome Regulatory Subunits 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
1 NP_081633.1 2 1.3 
2 NP_598862.1 5 1.0 
3 NP_033465.1 1 -1.1 
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4 NP_032973.1 4 -1.2 
6A NP_032974.2 1 -1.1 
7 NP_035318.1 2 -1.0 
10B NP_080235.2 1 1.2 
11 NP_848731.2 2 1.3 
12 NP_080170.1 2 -1.2 
14 NP_067501.2 1 -1.3 
 
 
E2/E3 Ubiquitin Ligases 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Birc6 NP_031592.3 11 1.3 
Hectd1 NP_659037.2 7 1.0 
Huwe1 NP_067498.4 29 -1.1 
Nedd4 NP_035020.2 2 -1.4 
RLIM NP_035406.3 3 -2.0 
Ube2n XP_001475660.2 2 1.1 
Ube3A 
(isoform 1) 
NP_766598.1 2 -1.3 
Ubr4 NP_001153791.1 2 1.9 
Ubr5 
(isoform 2) 
NP_001106192.1 3 1.3 
 
 
Transcription / Splicing / Translation Factors 
Name Reference Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Eef1-α1-like 
(isoform 3) 
XP_003946343.1 5 -1.2 
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Eef2 NP_031933.1 1 1.7 
EF-Tu 
(mitochondrial 
isoform 1) 
NP_766333.1 1 2.2 
Parp10 NP_001157048.1 1 -1.0 
PCBP2 
(isoform 1) 
NP_001096635.1 1 -1.5 
Ptrf NP_033012.1 2 -1.0 
RBM14 NP_063922.2 4 -1.5 
SAM synthase 
(isoform type-2) 
NP_663544.1 1 1.0 
Sub1 NP_035424.1 1 1.0 
U2AF 65 kDa 
subunit-like 
XP_003085312.1 2 -1.0 
 
 
Ribosomal Proteins 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
40S RPS3 NP_036182.1 5 -1.1 
40S RPS11 NP_038753.1 1 -1.1 
40S RPS15a NP_733769.1 1 -1.7 
40S RPS16-like XP_003688797.1 2 1.6 
40S RPS18 NP_035426.1 1 -1.8 
40S RPS20 NP_080423.1 2 -2.1 
40S RPS27-like NP_001177187.1 1 -1.5 
40S RPS27a-like XP_001002242.1 1 -1.4 
60S RPL23-like XP_003689266.1 3 -1.0 
60S RPL38 NP_001041522.1 1 -1.1 
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Trafficking/Targeting 
Name Reference Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Annexin A1 NP_034860.2 2 -1.4 
Annexin A2 NP_031611.1 1 -1.6 
Arf4 NP_031505.1 3 -1.0 
Asap2 
(isoform b) 
NP_001004364.2 1 1.0 
Get4 homolog 
(isoform 1) 
NP_080545.2 4 -1.1 
TER ATPase / Vcp NP_033529.3 15 1.0 
UBL4A NP_663380.1 3 -2.3 
Myosin-9 
(isoform 1) 
NP_071855.2 9 1.8 
Unconventional 
Myosin-Ic (isoform 
b) 
NP_001074243.1 1 10.7 
 
Chaperones 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Bag2 NP_663367.1 1 1.8 
Bag6 
(isoform 2) 
NP_001239397.1 16 -1.1 
GRP-78 NP_001156906.1 8 1.2 
Hsc70 NP_112442.2 11 1.0 
HSP 90β NP_032328.2 10 -1.5 
PDIA6 
(precursor) 
NP_082235.1 1 -1.2 
STCH 
(mitochondrial) 
NP_034611.2 6 1.3 
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Metabolism 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Adh1 P00330 1 -1.3 
ADP/ATP 
Translocase 1 
NP_031476.3 4 1.1 
ADP/ATP 
Translocase 2 
NP_031477.1 3 -1.4 
ATP Synthase, 
subunit E 
NP_031533.2 1 -1.4 
ATP Synthase, 
subunit α 
(mitochondrial 
precursor) 
NP_031531.1 1 2.0 
Carnitine O-
Palmitoyltransferase 
2 
(mitochondrial 
precursor) 
NP_034079.2 1 -1.0 
GAPDH-like 
(isoform 2) 
XP_001476757.1 10 -1.3 
LDHA chain 
(isoform 1) 
NP_034829.1 2 -1.9 
NADH 
dehydrogenase 1 
α subcomplex, 
subunit 4 
NP_035016.1 1 -2.2 
Phosphate Carrier 
Protein, 
mitochondrial-like 
(isoform 1) 
XP_001475977.1 2 -1.1 
Thioredoxin NP_035790.1 1 -1.5 
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Cytoskeletal Components and Modulators 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Actin 
(cytoplasmic 2) 
NP_033739.1 2 2.4 
Actin 
(α skeletal muscle) 
NP_033736.1 6 1.3 
Fascin NP_032010.2 1 1.5 
Fibronectin 
(Precursor) 
NP_034363.1 38 2.1 
Fibulin-2 
(isoform 
a)(Precursor) 
NP_032018.2 3 2.5 
Filamin-A NP_034357.2 1 1.3 
Keratin, type I 
(cytoskeletal 10) 
NP_034790.2 8 -1.1 
Keratin, type I 
(cytoskeletal 16) 
NP_032496.1 3 1.1 
Keratin, type I 
(cytoskeletal 17) 
NP_034793.1 4 1.5 
Keratin, type I 
(cytoskeletal 42) 
NP_997648.2 1 -1.1 
Keratin, type II 
(cytoskeletal 1) 
NP_032499.2 3 1.1 
Keratin, type II 
(cytoskeletal 2 
epidermal) 
NP_034798.2 4 1.1 
Keratin, type II 
(cytoskeletal 5) 
NP_081287.1 4 1.2 
Keratin, type II 
(cytoskeletal 73) 
NP_997650.1 1 1.7 
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Keratin, type II 
(cytoskeletal 78-like) 
XP_003086989.1 1 1.3 
Keratin, type II 
(cytoskeletal 79) 
NP_666175.1 1 1.4 
Lysyl Oxidase 
homolog 1 
(precursor) 
NP_034859.2 1 -1.3 
Lysyl Oxidase 
(Precursor) 
NP_034858.2 1 1.8 
Mxra8 
(precursor) 
NP_077225.4 1 -1.1 
Nestin NP_057910.3 1 2.0 
Pdlim7 
(isoform a) 
NP_001107560.1 1 -1.1 
Prelamin-A/C 
(isoform A) 
NP_001002011.2 5 -2.7 
Thrombospondin-1 
(Precursor) 
NP_035710.2 1 2.9 
Tubulin α-1B chain NP_035784.1 1 -2.0 
Tubulin α-1C chain NP_033474.1 11 -1.1 
Tubulin β-4B chain NP_666228.1 1 -1.1 
Tubulin β-5 chain NP_035785.1 11 -1.3 
Tubulin β-6 chain NP_080749.2 2 -1.7 
Vimentin NP_035831.2 3 1.4 
Zyxin NP_035907.1 5 -1.0 
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Other 
Name 
Reference 
Number 
Peptide 
Count 
Fold Change 
(KO v WT) 
Ankyrin Repeat 
Domain-Containing 
Protein 13A 
NP_080994.2 4 -1.2 
DDB1 NP_056550.1 6 -1.5 
Fhl2 NP_034342.1 1 2.0 
GPNMB 
(Precursor) 
NP_444340.3 1 2.0 
Iqca1 NP_083398.2 1 -1.1 
ITM2B NP_032436.1 1 -1.6 
Nischarin NP_073147.2 2 -1.4 
Olfr976 NP_666479.1 1 -1.2 
RNF213 XP_001476701.2 5 1.6 
Spata7 homolog NP_849245.2 1 -1.4 
Teneurin-1 NP_035985.2 1 1.4 
TGFβ1-induced 
transcript 1 protein 
NP_033391.1 3 -1.2 
ZNF334 NP_848498.2 1 1.0 
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